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ABSTRACT 
ATR (Ataxia Telangiectasia-mutated and Rad3-related) kinase acts as a central regulator 
and mediator of the replication checkpoint in response to DNA damage and replication 
stress. To initiate DNA repair, ATR induces a G2/M cell cycle arrest and stabilizes the 
replication fork during DNA synthesis. Pharmacological inhibition of ATR has recently been 
demonstrated to eliminate tumor cells in colorectal cancers (CRCs) but the underlying 
genetic determinants remain unexplained. Identification of these determinants is essential to 
develop novel tumor therapy strategies. Due to ATRs` essential role in DNA repair, synthetic 
lethal interactions of DNA repair mechanisms with ATR are suggested to mediate 
ATR-inhibitor specific tumor cell killing.  
Using the concept of synthetic lethality, a synthetic lethal screen was conducted in a 
genetically well-defined ATR knock-in model of DLD1 CRC cells to identify potential genetic 
determinants eliciting ATR inhibitor-specific tumor cell killing. Applying a siRNA library 
directed against 288 DNA-repair genes, a set of DNA-repair genes was identified whose 
knockdown caused either the selective killing of DLD1 ATR-deficient cells (n=6) or an ATR 
genotype-independent cell killing of DLD1 ATR-proficient and DLD1 ATR-deficient cells 
(n=20). 
The strongest synthetic lethal effect was observed between ATR and POLD1 confirmed by 
kinetic and titration analysis upon POLD1 knockdown in ATR-deficient cells. ATR genotype-
dependent POLD1 knockdown-induced cell killing was reproducible pharmacologically in 
POLD1-depleted DLD1 as well as a panel of other CRC cell lines by using chemical 
inhibitors of ATR or of its major effector kinase CHK1. Mechanistically, POLD1 depletion in 
DLD1 ATR-deficient cells caused caspase-dependent apoptosis without preceding cell cycle 
arrest and increased DNA damage along with impaired DNA repair, as demonstrated by 
elevated and sustained levels of γ-H2AX focus formation and pan-nuclear γ-H2AX staining. 
Irradiation-induced spatial co-localization of POLD1 with ATR as well as of POLD1 with 
γ-H2AX at sites of DNA damage was further detected. 
Notably, inactivating POLD1 mutations have recently been described in four families with 
multiple colorectal adenomas and CRC. In three of these families endometrial tumors were 
diagnosed. Considering that whole genome-sequencing might determine the POLD1 
mutation rates in different tumor entities, our data could have clinical implications in tumor 
genotype-based cancer therapy with regard to patients harboring those POLD1-deficient 
tumors, which might respond to chemical inhibition of the ATR/CHK1-axis. POLD1 deficiency 
might thus represent a predictive marker for treatment response towards ATR- or 
CHK1-inhibitors, which are currently tested in clinical trials. Long-term, the development of 
selective POLD1-targeted drugs might further broaden the applicability of the identified 
synthetic lethality with ATR-inhibitors.   
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ZUSAMMENFASSUNG 
DNA-Schäden lösen umfangreiche intrazelluläre Signaltransduktionskaskaden zur Erhaltung 
der genomischen Integrität aus. Die Kinase ATR (Ataxia Telangiectasia-mutated and Rad3-
related) vermittelt dabei die Aktivierung und Regulierung des Replikationscheckpunkts zum 
Anhalten des Zellzyklus sowie die Stabilisierung der Replikationsgabel, um eine gezielte 
DNA-Reparatur gewährleisten zu können. Eine pharmakologische Inhibition von ATR führte 
bereits zum Absterben von Tumorzellen in kolorektalen Tumoren, wobei die 
zugrundeliegenden genetischen Determinanten noch nicht identifiziert werden konnten. 
Aufgrund der zentralen Funktionen von ATR im Rahmen der DNA-Reparatur liegt jedoch 
nahe, dass insbesondere veränderte DNA-Reparaturmechanismen in diesen Tumoren hier 
eine Rolle im Sinne synthetisch letaler Beziehungen mit ATR spielen könnten. Die 
Identifizierung dieser Determinanten könnte daher als Basis für neue Tumortherapie-
konzepte dienen.  
Im Rahmen dieser Arbeit wurde ein Screening einer siRNA-Bibliothek, basierend auf dem 
Prinzip der synthetischen Letalität, mit 288 DNA-Reparaturgenen in einem genetischen ATR-
Knock-in-Modellsystem humaner kolorektaler Tumorzellen durchgeführt. Das Ziel war die 
Identifizierung genetischer Determinanten, die mit ATR synthetisch letal wirken. Es konnten 
mehrere DNA-Reparaturgene identifiziert werden, deren Ausschaltung das selektive 
Absterben von ATR-defizienten Tumorzellen induzierte (n=6). Desweiteren wurden auch 
DNA-Reparaturgene gefunden, deren Ausschalten zu einem ATR-unabhängigen Absterben 
von kolorektalen Tumorzellen (n=20) führte.  
Das Ausschalten von POLD1 zeigte den stärksten Effekt in ATR-defizienten Tumorzellen, 
der mittels Kinetik- und Titrationsexperimente bestätigt wurde. Potentiell klinische Relevanz 
erhalten diese Daten dadurch, dass die beobachteten Effekte nicht nur durch genetische 
ATR-Inhibition, sondern auch durch pharmakologische Inhibition sowohl von ATR selbst als 
auch seiner Haupt-Effektorkinase CHK1 in ähnlichem Maße ausgelöst werden konnten. 
Diese Daten ließen sich durch Untersuchung weiterer Tumorzelllinien generalisieren. 
Weiterführende Untersuchungen zum zugrunde liegenden Wirkmechanismus konnten ein 
vermehrtes Auftreten von DNA-Schäden und eine beeinträchtige DNA-Reparatur zeigen, 
dargestellt durch eine erhöhte und anhaltende Anzahl an γ-H2AX Foci sowie einer Caspase-
abhängige Apoptose ohne vorhergehenden Zellzyklusarrest in ATR-defizienten Tumorzellen 
nach dem Ausschalten von POLD1. Die zusätzlich nachgewiesene Ko-Lokalisation von 
POLD1 mit ATR sowie POLD1 mit γ-H2AX an Positionen mit DNA-Schäden nach IR in 
Tumorzellen unterstützt unsere Hypothese zum Wirkmechanismus (Apoptose als Folge von 
erhöhten DNA-Schäden bzw. verringerter DNA-Reparatur).  
Mutationen in POLD1 wurden bereits in niedriger Mutationsfrequenz in Patienten mit 
kolorektalen und endometrialen Tumoren beschrieben. Die hier erzeugten Daten könnten 
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daher als Basis zur Patientenstratifizierung für derzeit in klinischen Studien befindliche 
ATR/CHK1-Inhibitoren dienen und somit zur Individualisierung klinischer Therapieansätze 
beitragen. Langfristig könnte die Entwicklung spezifischer POLD1-Inhibitoren dazu dienen, 
die hier identifizierte synthetische Letalität als Kombinationstherapie mit ATR-Inhibitoren 
einem größeren Patientenkollektiv zugänglich zu machen.  
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1. INTRODUCTION
1.1. The DNA damage response (DDR)
1.1.1. DDR-mediated signal transduction
Each of the ~1013 cells of the human body is persistently challenged
lesions per day (1). These damages are caused by exogenous (environmental) or 
endogenous (spontaneous) stress. Environmental
chemically (chemicals, anti-tumor agents) or physically (ultraviolet (UV) light, ionizing 
radiation (IR)). Endogenously
deamination or oxidation via reactive oxygen species (ROS)
activate a complex DNA damage response (DDR) network. The DDR coordinates DNA 
replication and repair, cell cycle transition and apoptosis to ensure genome integrity and cell 
viability (4). The classical DDR pathways lead to the activation of a signal transduction 
cascade including DNA damage and replication stress detection, information transduction 
and execution of DDR functions by different repair mechanisms 
 
 
 
Figure 1: Schematic representation of DDR pathways.
endogenously-induced DNA lesions leading to stalled replication forks (and subsequent replication stress (RS)), 
single-strand breaks (SSBs) and double
activation of sensor, transducer (apical kinases, mediators, downstream kinases) and effector proteins. Proteins 
involved in ATR-mediated DDR signaling are exemplarily listed in brackets. ATR activation directly effects DNA
repair and cell cycle progression/arrest (illustrated by black
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-induced DNA lesions can be generated 
-induced DNA alterations are elicited by depurination, cytosine 
 (2; 3). These DNA lesions 
(5; 6) (Fig.
 The DDR network is activated by exogenously
-strand breaks (DSBs). Signaling of DNA lesions comprise
-bordered circles). Figure modified 
 
by up to 105 DNA 
 1).  
 
- and 
s consecutive 
-
according to (5; 7). 
INTRODUCTION 
__________________________________________________________________________ 
- 2 - 
 
1.1.2. DDR-mediated activation of DNA-repair pathways 
Once a DNA lesion is sensed by DDR, different DNA-repair pathways depending on the 
source of DNA damage, exogenously- or endogenously-induced, are activated (Table 1). 
 
Table 1: DNA-repair mechanisms in DDR. 
 
DNA-repair 
mechanism 
 
DNA lesion Inducer of DNA 
lesions 
DNA-repair mediators; 
Comments 
References 
Homologous 
recombination  
(HR) 
• DSBs* 
• Stalled replication 
forks 
• Unrepaired SSBs 
 
• BRCA1/2 
• FA protein 
• Error-free 
• Intact sister chromatid 
template required  
• S and G2/M cell cycle 
phase association 
 
(8-11) 
Non-homologous 
end joining (NHEJ) 
• DSBs* 
 
• ROS 
• IR 
• Core proteins 
KU70/KU80 
• Not error-free 
• No sequence homology 
required  
• Predominantly G0/ G1 
(8-11) 
 
 
Single-strand 
break repair  
(SSBR)** 
 
 
• SSBs 
 
 
• IR 
 
• PARP proteins 
• XRCC1 
• DNA polymerase δ/ε  
 
(10) 
Nucleotide-
excision repair  
(NER) 
• Helix-distorting 
lesions (large DNA 
adducts, base 
modifications) 
• Intrastrand and 
interstrand 
crosslinks (ICLs)  
 
 
• UV, tobacco 
smoke, afflatoxin 
 
 
• Platinum-based 
agents 
• XP proteins 
• ERCC1 
• XRCC1 
• DNA polymerase δ/ε 
 
(12) 
Base-excision 
repair (BER)** 
• Non-helix-
distorting  
 
• DNA strands with 
damaged bases  
• SSBs 
 
• Base modification 
(deamination, 
loss) 
• ROS 
• IR 
• PARP proteins 
• XRCC1 
• DNA polymerase δ/ε  
 
(10) 
Mismatch repair  
(MMR) 
• Mismatched 
nucleotides 
• Insertions  
• Deletions  
 
• Replication 
errors*** 
• Base 
deamination 
 
• MSH 
• MLH 
• PCNA proteins 
• DNA polymerase δ 
 
(13; 14) 
O6-methylguanine 
DNA methyl-
transferase 
(MGMT) 
• Erroneous 
alkylation at the 
O6- position of 
guanine 
• SAM  • DNA methyltransferase 
• Direct reversal of DNA 
lesions 
 
(10) 
* DSBs display the most difficult DNA lesions. 
** BER and SSBR are often assumed to be synonymous but differ in initial DNA lesion recognition. Whereas BER 
generates a SSB after removing of a damaged base, existing SSBs directly induce SSBR. 
*** Replication errors are induced by insufficient intrinsic proofreading activity of DNA polymerases during DNA 
synthesis. 
SSBs, single-strand breaks; DSBs, double-strand breaks; SAM, S-adenosyl methionine; ROS, Reactive oxygen 
species, UV, ultraviolet light; IR, ionized radiation; XP, xeroderma pigmentosum; FA, Fanconi anemia 
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1.1.3. Targeting DNA-repair pathways for cancer therapy 
DDR and repair mechanisms are essential to cope with exogenously and endogenously-
induced DNA lesions to maintain genomic stability. In order to exploit the DDR and DNA 
repair mechanisms for anticancer therapeutic approaches, different aspects have to be taken 
into consideration. 
Firstly, chemo- and radiotherapy cause massive unspecific DNA damage. Their cytotoxic 
effects depend on the cellular DDR and DNA-repair mechanisms. Secondly, vice versa, an 
increased DNA-repair activity is suggested to be correlated with resistance to chemo- and 
radiotherapy, which represents one major obstacle in cancer treatment. Thirdly, 
predisposition to cancer can be associated with germline and infrequently arising somatic 
mutations of DDR genes, alterations of DDR proteins and epigenetic changes. Loss of 
function or down-regulation of DNA-repair genes in cancer results in hypersensitivity to DDR 
protein-targeted drugs. Fourthly, the loss of a distinct DDR pathway can activate tumor-
specific compensatory DNA-repair mechanisms (15). 
The understanding of DDR network along with the identification of potentially druggable 
DNA-repair proteins have provided the basis to exploit cancer-associated DDR alterations. 
DNA-repair inhibitors are often used in a combination therapy with chemo- or radiosensitizers 
to potentiate cytotoxicity. In solid cancer treatment, platinum chemotherapeutics (cisplatin, 
oxaliplatin, carboplatin) are known to form DNA adducts but are often associated with 
resistance, which is caused by an increased cellular repair activity. It has been shown that a 
combination therapy with PARP inhibitors (16) or the protein kinase inhibitor UCN-01 (17) 
can circumvent platinum resistance. In radiotherapy, it has been reported that the DNA-
dependent protein kinase inhibitor NU7441 sensitizes cancer cells to IR. Inhibition of NHEJ 
by NU7441 prevents IR-induced DSBs repair (18). Furthermore, several PARP inhibitors 
undergo clinical testing as a single agent cancer therapy (10). However, the administration of 
DNA-repair inhibitors as monotherapy entails advantages and limitations. In general, single-
agent therapies increase treatment selectivity, thus reduce unspecific side effects. 
Nevertheless, cross-talk between overlapping DNA-repair pathways also reduces single-
agent activity and promotes acquisition of resistance mechanisms. To overcome cross-talk-
induced resistance, the exploitation of synthetic lethal interactions is a possible concept to 
increase DNA-repair inhibitor selectivity and potency to achieve an exclusive cancer 
cytotoxicity (9). The principle of synthetic lethality is described in paragraph 1.3.  
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1.2. Ataxia telangiectasia mutated and RAD3-related (ATR) 
1.2.1. ATR-mediated checkpoint signaling and DDR 
The DDR network senses DNA damage and replication stress leading to a signal cascade 
activation primarily mediated by apical kinases of the phosphoinositide 3-kinase 
(PI3K)-related protein kinase (PIKK) family. These serine/threonine kinases include DNA-
PKcs, mTOR, SMG1, ATM and ATR (19). The following part will focus on the role of ATR in 
cell cycle checkpoint signaling and DDR, as illustrated in Figure 1. 
ATR is essential for the viability of replicating cells (20) due to its influences in cell cycle 
checkpoint signaling and DNA-damage repair (21). Although ATR-mediated DDR is initiated 
by single-stranded DNA structures, arising at double-strand breaks (DSBs), base adducts 
and crosslinks (19), ATR is mainly a replication stress (RS)-response kinase (4). Despite the 
different types of DNA lesions and RS events, single-stranded DNA (ssDNA) is suggested to 
be responsible for ATR activation (22). ssDNA is sensed and rapidly coated by RPA proteins. 
The ATRIP protein directly binds to RPA and recruits ATR to ssDNA (23). An RPA-coated 
ssDNA might be sufficient for ATR-ATRIP complex recruitment, however its interaction is not 
sufficient to activate ATR (4). Therefore, ATR signaling requires primed ssDNA with free 
5´primer ends (24) and co-localization of the RAD9-RAD1-HUS1 (9-1-1) protein complex 
(19). The 9-1-1 complex recruits the critical ATR activator TOPBP1, containing an ATR 
activation domain (AD).  
Once activated, ATR promotes transient cell cycle arrest, DNA-repair, replication fork 
stabilization and restart via its downstream targets (4). In detail, ATR signaling is mediated 
by phosphorylation of its major downstream kinase CHK1. ATR-CHK1 interaction is 
regulated by the adaptor protein CLASPIN (25). CHK1 activation mainly leads to the 
phosphorylation of CDC25 phosphatases (CDC25A-C), which inhibits their own activity. In 
detail, CDC25A phosphorylation inhibits replication origin firing during S-phase, which results 
in DNA replication slowdown and ensures proper DNA-repair conditions as a consequence of 
exogenously- or endogenously-induced DNA damage. The cell cycle S-phase is re-activated 
by CDC25A degradation and CDK1-CYCLIN E kinase regulation (4; 21). Further, G2/M cell 
cycle checkpoint signaling is regulated by CHK1-dependent CDC25A and CDC25C 
phosphorylation, which prevents premature mitosis entry (4).  
Overall, ATR activation mediates S-phase arrest ensuring DNA repair by slowing DNA 
replication progress and preventing premature entry into mitosis, which is defined as 
ATR-induced replication stress response (RSR) (26).  
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1.2.2. Development of ATR-inhibitors for cancer therapy 
Since ATR has been identified as an essential gene in mouse early embryogenesis (27), 
pharmacological inactivation of ATR was not taken into further consideration for specific 
inhibitor development.  
Currently, it is believed that only hypomorphic or heterozygous ATR mutations with 
haploinsufficient features are compatible with cell viability (28). Based on this assumption, a 
human hypomorphic ATR mutation has been reported to cause the rare hereditary Seckel 
syndrome disorder (29). Studies of a mouse model harboring Seckel syndrome mutation 
could show that hypomorphic ATR depletion increases sensitivity of cancer cells to 
oncogene-induced replication stress (30). This finding reconsidered ATR inhibition as 
possible cancer strategy promoting ATR-inhibitor development. 
Different studies identified the role of ATR in tumorigenesis. During early lesions, the ATR-
dependent RSR prevents tumor growth, while in advanced stages, ATR activation promotes 
tumor progression (28; 31). Therefore, exploitation of the ATR-dependent RSR might be a 
potent strategy in cancer therapy.  
The first available small molecule ATR-inhibitor was caffeine, which lacked potency and 
selectivity (32). Recently, several compounds were identified as effective ATR-inhibitors, e.g. 
VE-821 or AZ20. The further development of these ATR-targeting drugs and investigations in 
ongoing clinical trials show the potential of ATR inhibition, e.g. for VE-822 or AZD6738 
(Table 2). 
 
1.2.3. Targeting ATR in mono-and combination cancer therapy 
ATR inhibition is considered to be a promising therapeutic target in combination with chemo- 
and radiotherapy. It has been reported, that various chemotherapeutics with different mode 
of actions sensitize cells to ATR inhibition, e.g. gemcitabine, 5-fluorouracil (5-FU) and 
platinum derivates. Gemcitabine, a cytidine analogue, misincorporates into the DNA and 
elicit DNA damage and replication fork stalling. Platinum chemotherapeutics form intra- and 
interstrand DNA adducts that result in bulky distortion of the DNA (33). However, in the 
clinical setting, a potent and selective monotherapy of DDR-targeted drugs, with few side 
effects, is aspired. Single agent activity has been exclusively reported for the ATR-inhibitors 
AZ20 and AZD6738 in either MRE11- or ATM-deficient cells so far (34; 35). VE-822, 
AZD6738 and NVP-BEZ235 are as yet the only ATR-inhibitors undergoing clinical testing 
(Table 2).  
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Table 2: Recently identified and developed ATR-inhibitors. 
 
ATR inhibitor 
 
Inhibitory effect Comments Reference 
NU6027 • Originally developed as CDK2 
inhibitor  
• Phosphorylation inhibition of 
CHK1 at Ser345 
 
• Sensitivity in µM range  
• Lacks selectivity 
• Sensitivity to DNA-damaging agents/IR 
 
(36) 
VE-821 • Phosphorylation inhibition of 
CHK1 at Ser345 
• Sensitivity in µM range 
• Potent and selective  
• Sensitivity to DNA-damaging agents/IR 
• Single agent activity in hypoxic cells 
 
(37-39) 
VE-822  
(VX-970)  
• Analogue of VE-821 
• Phosphorylation inhibition of 
CHK1 at Ser345 
• Sensitivity in nM range 
• Increased potency and selectivity  
• Improved pharmacokinetic properties 
• Sensitivity to DNA-damaging 
agents/IR/gemcitabine 
• 1st ATR inhibitor entering clinical trials  
 
(33) (40) 
(ClinicalTri
als.gov: 
NCT02157
792) 
  
AZ20 • Phosphorylation inhibition of 
CHK1 at Ser345 
 
• Sensitivity in nM range  
• Potent and selective 
• Single agent activity in vivo 
 
(34) 
AZD6738 • Analogue of AZ20 
• Phosphorylation inhibition of 
CHK1 at Ser345 
 
• Increased potency and selectivity 
• Improved pharmacokinetic properties 
• Single agent activity in vivo 
• Sensitivity to IR and carboplatin 
• Clinical trial phase I investigations 
 
(35) 
(Clinical 
Trials. gov: 
NCT02223
9239) 
ETP-46464 • Leading to stalled replication 
fork breakage 
 
• Sensitivity in nM range 
• Potent and selective 
(41) 
NVP-BEZ235 • Originally developed as a dual 
PI3K and mTOR inhibitor  
• Destabilization of stalled 
replication forks  
• Sensitivity in nM range 
• Potent and selective 
• Clinical trial phase I investigations 
 
(41) (42) 
  
__________________________________________________________________________
 
1.3. Synthetic lethality
Synthetic lethality is defined as interaction of two non
viability (43; 44) and is induced by ei
inhibitor treatment (Fig. 2B). Genome
identify unknown synthetic lethal gene interactions in cancer cells harboring ´non
oncogenes´ or ´absent tumor suppressors´ with new or already known and druggable gene 
targets, which are not previously associated with cancer 
approaches have the advantage to elicit tumor specificity because non
least one functional gene of the targeted synthetic lethal gene interaction. In clinical 
application, synthetic lethality exploits tumor
potentiate a weak single-agent anticancer activity in certain subpop
Furthermore, this concept represents a more selective and tumor
besides the classical less-se
window and causing tissue-independent toxicity and pa
Therefore, synthetic lethal approaches
therapy in personalized medicine. 
 
 
A 
Figure 2: The principle of synthetic 
lethal mutations are incompatible with cell viability. Concerning therapeutic approaches, synthetic lethality is 
induced by (A) classical gene knockdown or (
 
 
1.3.1. Exploitation of deregulated DDR by synthetic lethality
Alterations in DDR pathways lead to genomic instability and predispos
and endogenous genotoxic stress, 
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radiotherapy (10). The loss of a DDR pathway can lead to a compensatory DNA-repair gene 
activation (9). These compensatory pathways are particularly exploitable in DDR-defective 
tumors through synthetic lethal approaches. Utilizing the concept of synthetic lethality, one of 
the most striking examples for this approach is illustrated by the inhibition of PARP in BRCA1 
and BRCA2-deficient cancers (48; 49). Several other synthetic lethal interactions of DDR 
pathway genes have been reported so far (reviewed in (9; 11)). 
 
1.3.2. Synthetic lethal interactions of ATR with DDR-associated and other genes 
To date, little is known about synthetic lethal interactions between ATR and DDR genes. 
ATR inhibition induces synthetic lethality with ATM, encoding another apical kinase of the 
DDR network (38), XRCC1, encoding a component of the BER and NER pathways (50) and 
ERCC1, a gene, which is mainly associated with NER and further with HR and single-strand 
annealing (51). ATR-inhibitors also exhibit synthetic lethality with p53 deficiency (38) as well 
as with oncogenic RAS and CYCLIN E overexpression (41; 52). 
Genome-wide functional screens and the development of specific ATR inhibitors will promote 
the identification of novel synthetic lethal interaction partners of ATR. For clinical application, 
patient stratification regarding already known ATR synthetic lethal interactors and the 
improvement of ATR-inhibitors with regard to therapeutic efficacy and pharmacological 
properties might improve clinical trial designs and might benefit the clinical outcome in 
personalized cancer therapy.  
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1.4. Colorectal cancer (CRC) 
1.4.1. Epidemiology of CRC 
With over one million cases per year, CRC is one of the major cancer-related diseases 
worldwide (53). In men, CRC is the third most common malignancy after lung and prostate 
cancer. In women, CRC is registered as second most common malignancy after breast 
cancer (54). The CRC incidence rate varies widely and depends on age, socioeconomic 
status connected with 'modern lifestyle' and geographic area distribution as well as disease 
predisposition. A low CRC incident rate is seen up to 50 years of age, however with 
advanced age, the number of CRC patients is increasing (54). In Europe and in the US, the 
incidence rate is 10-fold higher compared to African and Asian countries, which is associated 
with the socioeconomic status of industrial and developing countries. 13% of the European 
and 8% of men and women from the US with CRC have an estimated mortality rate of 12% 
and 9%, respectively (55; 56). In 5-10% of all CRC cases, hereditary syndromes are 
associated with CRC development, such as HNPCC (hereditary non-polyposis CRC) and 
FAP (familial adenomatous polyposis) (57). Furthermore, 20% of CRCs occur among the 
patient's first-degree family members (54), whereas inflammatory diseases, such as 
ulcerative colitis and Crohn's disease, are main predisposing factors to CRC (58). However, 
the vast majority of CRC cases are of sporadic origin with no identifiable genetic risk factor.  
 
1.4.2. Genetic and epigenetic patterns in CRC pathogenesis 
CRC is defined as a heterogeneous disease caused by genetic (sporadic and hereditary 
origin) and epigenetic changes (59). Although 15-30% of CRC patients harbor hereditary 
components, the majority of colorectal tumors arise through sporadic accumulation of 
different gene mutations (60). In 1990, a genetic model for colorectal neoplasia was 
proposed by Fearon and Vogelstein describing oncogene activation (e.g. RAS) coupled with 
tumor suppressor gene inactivation (e.g. p53) as potential tumor promoting factors (61) 
leading to an increased clonal cell expansion, which promotes invasive cancer growth (60). 
Currently, three major CRC pathogenesis mechanisms have been identified as being the 
chromosomal instability (CIN) with an incidence of 60-80% (62; 63), the microsatellite 
instability (MSI) with an 13-20% incidence (62; 64; 65) and CpG island methylator phenotype 
(CIMP) with a frequency of 5-15% (59; 65). New insights into CRC pathogenesis imply that 
CRC does not arise by one distinct genetic mechanism, e.g. the mutual exclusiveness of 
MSI or CIN (53). Several studies associated different genetic and epigenetic CRC 
characteristics together with molecular profiles (different gene mutations) and clinical-
pathological features (tissue morphology and location), which underlines the complexity of 
CRC tumorigenesis and progression (65-69). 
__________________________________________________________________________
 
The most common form of genomic instability in CRC is CIN 
activation of proto-oncogenes
suppressor genes, such as APC
chromosome 18 (18q LOH) (63; 70; 71)
tumorigenesis (72).  
In a subgroup of patients, CRC is 
repair (MMR) response. MSI is related to aberrant CpG promoter methylation of 
point mutations in MMR genes 
frameshift mutations (insertions, deletions) in microsatellite regions
non-coding DNA sequences, 
is classified into MSI-high (MSI
stable).  
MSI and CIN correlate with the 
aberrant promoter sequences, which 
genes and DNA-repair genes, such as 
significant mutations in BRAF
CIMP-low, CIMP negative) (73)
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CpG island methylator phenotype (CIMP)
 
Figure 3: Genetic and epigenetic 
associated with CRC tumorigenesis: 
CpG island methylator phenotype (CIMP)
and BRAF (C). Figure modified according 
INTRODUCTION 
- 10 - 
characterized by a
, such as KRAS, c-MYC, c-SRC, PI3KCA, inactivation of 
 and p53, and loss of heterozygosity for the long arm of 
. (Fig. 3A). Usually, mutations in 
related to MSI caused by defects in the 
(60). In detail, cells with impaired MMR tend to
 encoding 
which subsequently lead to genomic instability
-H, ≥30%), MSI-low (MSI-L, 10-30%) and MSS (microsatellite 
CIMP status in CRC. CIMP is defined as hypermethylation
results in transcriptional silencing of tumor suppressor 
MLH1 (Fig. 3C). Further, CIMP
 (69) and is classified into different subgroups (CIMP
.  
 
 
 and BRAF mutation
events involved in CRC pathogenesis. Three distinct pathways are 
(A) Chromosomal instability (CIN), (B) Microsatellite instability (MSI) and (
, accompanied by gene mutations of APC (A+B), 
to (60). 
 
neuploidy, 
tumor 
APC initiate CRC 
DNA mismatch 
MLH1 or 
 accumulate 
small repetitive 
. (Fig. 3B). MSI 
 of 
 correlates with 
-high, 
 
 
 
C) 
p53 (A+C), KRAS (A) 
INTRODUCTION 
__________________________________________________________________________ 
- 11 - 
 
1.4.3. Predictive and prognostic markers for CRC therapy 
An ongoing challenge is to translate CRC-related genomics and epigenomics into clinical 
prognosis and prediction (Table 3). Currently, the assessment of the patients' clinical-
pathological stage is based on the tumor-node-metastasis (TNM) classification, which 
remains the gold standard for prognosis (74). Nevertheless, the identification and validation 
of new prognostic and predictive genetic markers can improve and individualize a patient-
specific therapy concerning drug efficacy maximization and cytotoxic side effect minimization 
(75). 
 
Table 3: Clinically applicable prognostic and predictive genetic markers in CRC. 
 
Genetic marker 
 
Prognosis/Prediction References 
Prognostic 
  
Chromosome 18q • LOH associated with a poorer prognosis 
• Worse prognosis for down-regulated SMAD 2 and SMAD4 (located on 
chromosome 18q ) 
 
(76) 
APC mutation • High risk of CRC development with APC germline mutations  
• APC mutations in 90% of CRC patients 
• Prophylactic colectomy or proctocolectomy in patients with germline APC 
mutations 
 
(59; 77) 
KRAS mutation  • Worse prognosis for substitution in codon 12 (G->V) 
 
(78; 79) 
BRAF mutation  • Poorer prognosis for V600E mutation 
• KRAS downstream signaling to BRAF 
 
(79) 
EGFR  
 
• Poorer prognosis for EGFR overexpression  (80) 
Thymidylate 
synthase (TS) 
• Poorer prognosis for TS overexpression  (81) 
 
Predictive 
  
KRAS mutation • No response to EGFR inhibitor therapy (panitumumab and cetuximab) 
 
(82; 83) 
BRAF mutation 
 
• V600E mutation 
• KRAS downstream signaling to BRAF 
• No response to EGFR inhibitor therapy (panitumumab and cetuximab)  
 
(84) 
Thymidylate 
synthase (TS) 
• Decreased survival for patients highly expressing TS with 5-FU therapy (85) 
 
Prognostic markers provide information about the disease-related history and the likely 
course in non-treated individuals. For prognosis, germline mutations in tumor suppressor 
genes, such as APC, MLH1 and MSH2, are associated with a high risk of CRC (77; 86). MSI 
is correlated with a favorable prognosis (86; 87), whereas CRC patients with a CIN pattern 
show a worse survival (88). In contrast, predictive markers correlate with the response and 
the impact to a specific drug treatment to evaluate patient-specific benefit (53). An 
established marker for prediction is KRAS associated with resistance to EGFR-inhibitor 
therapy (82; 83).  
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1.4.4. Treatment strategies in CRC therapy 
Different types of treatment strategies are available for CRC patients. The most important 
strategy to improve survival of patients is the early detection of CRC. The most efficient 
treatment for early stage colon cancer is the removal of polyps by colonoscopy or by 
abdominal surgery (partial colectomy). Classical surgical resection is accompanied by 
adjuvant treatment with radio- and chemotherapy to control and restrict tumor growth as well 
as to reduce tumor recurrence after resection (74). However, radio- and chemotherapy are 
limited by a narrow therapeutic window and tissue-independent toxicity causing unselective 
side effects. Currently, new therapeutic strategies in the form of humanized monoclonal 
antibodies are developed to specifically affect molecular pathways critical for tumor growth 
and survival (74). However, therapies applying humanized monoclonal antibodies are likely 
to be more beneficial for CRC patients in combination with basic chemotherapies (89). 
Nonetheless, potent and selective monotherapies with few side effects are aspired in the 
clinical setting. New technologies like blood-based screenings of biomarkers with high CRC 
specificity are also currently under development (90) and should further improve early CRC 
detection, prognosis and prediction of treatment responses. 
 
Table 4: Chemotherapeutic agents in systematic CRC treatment. Monoclonal antibody, noted mAb. 
 
Therapeutic agent 
 
Comment Mechanism of action References 
Bevacizumab 
(Avastin®) 
• Targeted therapy 
• Anti-VEGF mAb (humanized 
antibody against all VEGF-A 
isoforms) 
 
• Antiangiogenesis (Prevention of 
VEGF receptor 2 signaling through 
VEGF-A antibody binding) 
(91) 
Cetuximab 
(Erbitux®) 
• Targeted therapy 
• Anti-EGFR mAB (IgG1 
subclass, chimeric 
mouse/human antibody) 
 
• Antineoplastic 
• Inhibition of EGF receptor 
downstream signaling including 
RAS-RAF-MAPK axis (cell 
proliferation) and PI3K-PTEN-AKT 
axis (cell survival) 
 
(92) 
Irinotecan 
(Camptosar®) 
• Derivate of camptothecin 
(topoisomerase I 
inhibitor),small molecule 
  
• Antineoplastic 
• Inhibition of topoisomerase I 
• Increased DNA fragmentation and 
apoptosis induction  
 
(93) 
Fluorouracil 
(Fluoroplex®) 
• fluorinated pyrimidine, small 
molecule 
• Antineoplastic  
• Inhibition of thymidylate synthase 
 
(89) 
Oxaliplatin 
(Eloxatin®) 
• Platinum derivate, small 
molecule  
 
• Antineoplastic 
• DNA adduct formation, impaired 
DNA synthesis/replication and 
apoptosis induction 
 
(94) 
Panitumumab 
(Vectibix®) 
• Targeted therapy 
• Anti-EGFR mAB (IgG2 
subclass, fully human 
antibody) 
• Antineoplastic 
• Inhibition of EGF receptor 
downstream signaling including 
RAS-RAF-MAPK axis (cell 
proliferation) and PI3K-PTEN-AKT 
axis (cell survival) 
(92) 
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Various drugs already in clinical application (Table 4), e.g. irinotecan, 5-FU and oxaliplatin, 
are currently undergoing randomized clinical studies as single agent or combination therapy 
with chemotherapeutics already used in clinical CRC treatment (74) targeting DNA synthesis 
or DNA-repair mechanisms (10). DNA damage is detected and resolved by a complex 
genome maintenance system to permit high rates of spontaneous mutations in each cell 
generation (10). If DNA lesions are not removable, cells are forced into apoptosis (6), which 
serves as natural barrier to tumorigenesis (95). However, cancer cells developed different 
strategies to restrict or circumvent DNA damage-induced apoptosis in order to achieve 
replicative immortality, a hallmark of cancer (96), e.g. the activation of compensatory DNA-
repair mechanisms (9). Thus, targeting DNA-damage signaling and repair proteins is a 
promising rationale in colorectal anti-cancer treatment strategies. 
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1.5. Aim of the project 
ATR (Ataxia Telangiectasia-mutated and Rad3-related) kinase acts as central regulator and 
mediator of the replication checkpoint in response to DNA damage and replication stress. To 
initiate DNA repair, ATR induces a S-phase arrest and stabilizes the replication fork during 
DNA synthesis. Pharmacological inhibition of ATR has been reported to specifically eliminate 
tumor cells in colorectal cancers (CRCs) but the underlying genetic determinants remain 
unexplained. Based on ATRs' central role in DNA damage response, synthetic lethal 
interactions with DNA-repair genes might provide the underlying genetic mechanism leading 
to ATR inhibitor-specific tumor cell killing. Therefore, the purpose of this study was to clarify 
the genetic background of ATR inhibitor-specific tumor cell killing and to introduce novel 
therapeutic strategies with ATR-targeting drugs. The specific aims of this project are: 
 
 
 
 
1. To identify potential synthetically lethal interactions between ATR and DNA-repair genes 
by applying a siRNA library screening approach of all major DNA-repair genes in a 
genetically well-defined ATR knock-in DLD1 CRC cell model.  
 
2. To analyze the underlying mechanisms mediating the synthetic lethal interactions 
between ATR and the identified DNA-repair genes.  
 
3. To test whether the pharmacological inhibition of ATR or its major effector kinase CHK1 
elicits similar synthetically lethal effects as genetic ATR inactivation does, using common 
preclinically and clinically used ATR- and CHK1-targeting agents. 
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2. MATERIAL AND METHODS 
2.1. Material 
2.1.1. Chemicals 
5-fluorouracile (5-FU)    Medac, Wedel, Germany 
Acetic acid      Merck, Chemicals, Darmstadt, Germany 
Acryl-bisacrylamide    Bio-Rad Laboratories GmbH, Munich, Germany 
Actinomycin D    Sigma-Aldrich GmbH, Steinheim, Germany 
β-Mercaptoethanol    Sigma-Aldrich GmbH, Steinheim, Germany 
Bovine serum albumin (BSA)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Bromophenol blue    Serva, Heidelberg; Germany 
Dimethyl sulfoxide    Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
DN/RNase free H2O    Qiagen GmbH, Hilden, Germany 
dNTPs (dATP, dTTP, dGTP, dCTP)  KapaBiosystems Ltd., London, UK 
Ethylenediaminetetraacetic acid (EDTA) Merck KGaA, Darmstadt, Germany 
Ethanol     Merck, Chemicals, Darmstadt, Germany 
Hoechst 33342     Sigma-Aldrich GmbH, Steinheim, Germany 
Ficoll® PM 400 Type 400   Sigma-Aldrich GmbH, Steinheim, Germany 
Glycerol     Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
β-Glycerophosphate    Sigma-Aldrich GmbH, Steinheim, Germany 
Glycine     Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Methanol     Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Mitomycin C (MMC)    Sigma-Aldrich GmbH, Steinheim, Germany 
Non-fat dry milk    Bio-Rad Laboratories GmbH, Munich, Germany 
Orange G     Sigma-Aldrich GmbH, Steinheim, Germany 
Oxaliplatin     Accord Healthcare, Freilassing, Germany 
Pierce ECL Western Blotting Substrate Thermo Scientific, Rockford, IL, USA 
Propidium iodide    Sigma-Aldrich GmbH, Steinheim, Germany 
Sodium dodecyl sulfate (SDS)  Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Sodium chloride    Sigma-Aldrich GmbH, Steinheim, Germany 
Sodium fluoride    Sigma-Aldrich GmbH, Steinheim, Germany 
Sodium orthovanadate   Sigma-Aldrich GmbH, Steinheim, Germany 
Sodium pyrophosphate   Sigma-Aldrich GmbH, Steinheim, Germany 
Sodium hydroxide    Merck, Chemicals, Darmstadt, Germany 
SuperSignal West Dura    Thermo Scientific, Rockford, IL, USA 
Chemoluminescent Substrate 
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SuperSignal West Pico   Thermo Scientific, Rockford, IL, USA 
Chemoluminescent Substrate 
SYBR Green Nucleic Acid Gel Stain  Lonza, Fisher Scientific GmbH,  
      Schwerte, Germany 
TEMED     Bio-Rad Laboratories GmbH, Munich, Germany 
TNFα      Perbio Science AB, Helsingborg, Sweden 
Tris-Base     Roche Diagnostics GmbH, Mannheim, Germany 
Tris-HCl     Roche Diagnostics GmbH, Mannheim, Germany 
Triton X-100     Carl Roth GmbH & Co.KG, Karlsruhe, Germany 
Trypan blue     Sigma-Aldrich GmbH, Steinheim, Germany 
Tween®20     Sigma-Aldrich GmbH, Steinheim, Germany 
 
2.1.2. Biochemical reagents 
Agarose (Crystal Agarose)   Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Ethidiumbromide (10 mg/mL)   Carl Roth GmbH & Co. KG, Karlsruhe, Germany 
Oligofectamin™ Reagent   Invitrogen, Life Technologies GmbH,  
      Darmstadt, Germany 
 
2.1.3. Antibodies 
The following antibodies were used for immunoblotting detection. 
 
2.1.3.1. Primary Antibodies 
anti-β-ACTIN (Host: mouse)   Sigma-Aldrich GmbH, Steinheim, Germany 
anti-ATR (N-19, sc-1887, Host: goat) Santa Cruz Biotechnologies Inc., 
      Heidelberg, Germany 
anti-CASPASE3 (Host: rabbit)  Cell Signaling Technology, Boston, MA, USA 
anti-CASPASE8 (Host: rabbit)  R&D Systems, Inc., Abingdon, UK 
anti-CASPASE9 (Host: rabbit)  Cell Signaling Technology, Boston, MA, USA 
anti-PARP (Host: rabbit)   Cell Signaling Technology, Boston, MA, USA 
anti-phosphoH2AX    Cell Signaling Technology, Boston, MA, USA 
(Ser139, 20E3, Host: rabbit) 
anti-phosphoH2AX (Ser139, Host: mouse) Upstate Biotechnology Inc., NY, USA 
anti-POLD1     Santa Cruz Biotechnologies Inc., 
(DNA pol # cat, sc-8797, Host: goat) Heidelberg, Germany 
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2.1.3.2. Secondary Antibodies 
2.1.3.2.1. HRP-conjugated antibodies 
anti-mouse HRP-conjugated   GE Healthcare,  
      PAA Laboratories GmbH, Pasching, Austria 
anti-goat IgG-HRP    Santa Cruz Biotechnologies Inc., 
(sc-2352, Host: bovine)   Heidelberg, Germany 
anti-rat HRP-conjugated   GE Healthcare, PAA Laboratories GmbH, 
      Pasching, Austria 
2.1.3.2.2. Fluorochrome-conjugated antibodies 
anti-goat Alexa Fluor®488   Life Technologies GmbH, Darmstadt, Germany 
(Host: donkey) 
anti-goat Rhodamine Red™-X-conjugated Jackson ImmunoResearch Laboratories, Inc., 
(Host: donkey)    West Grove, PA, USA 
anti-mouse Alexa Fluor® 488   Life Technologies GmbH, Darmstadt, Germany 
(Host: goat) 
 
2.1.4. Antibiotics 
Penicillin-Streptomycin (P/S)   PAA Laboratories GmbH, Pasching, Austria 
 
2.1.5. Inhibitors 
2.1.5.1. ATR inhibitors 
NU6027     Merck, Darmstadt, Germany 
VE-822      MedKoo Bioscience, Chapel Hill, NC, USA 
CHK1 inhibitors 
LY2603618     Selleckchem, Munich, Germany 
UCN-01     Sigma-Aldrich GmbH, Steinheim, Germany 
 
2.1.5.2. Protease inhibitor 
Protease Inhibitor Cocktail Set 1  Calbiochem, Merck, Darmstadt, Germany 
 
The ready-to-use Protease Inhibitor Cocktail Set 1 was dissolved in 1 mL ddH2O, aliquoted to 
50 µL samples and stored at -20 °C. Ingredients of the Protease Inhibitor Cocktail Set 1 are 
listed in Table 5. 
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Table 5: Content of Protease Inhibitor Cocktail Set 1. 
Inhibitor Concentration (1x) Target Protease 
 
AEBSF 
 
500 µM 
 
Serine Proteases 
Aprotinin 150 nM Serine Proteases and Esterases 
E-64 1 µM Cysteine Proteases 
EDTA 0.5 mM Metalloproteases 
Leupeptin 1 µM Cysteine Proteases and Trypsin-
like Proteases 
Hemisulfate 1 µM Cysteine Proteases and Trypsin-
like Proteases 
 
 
2.1.6. siRNA oligonucleotide 
2.1.6.1. Single siRNA oligonucleotide 
All siRNA oligonucleotide samples (1 nmol), except anti-β Gal siRNA 1 (Dharmacon 
Lafayette, Co, USA) were purchased from Qiagen GmbH, Hilden, Germany, diluted to a 
stock concentration of 20 µM and stored at -20 °C, according to the Qiagen siRNA protocol. 
Targeted sequences of all siRNAs are shown in Table 6.  
 
Table 6: siRNA oligonucleotides and their target sequences. 
siRNA oligonucleotide Target sequence 
 
anti-β Gal siRNA 1 
 
5'-TTATGCCGATCGCGTCACATT-3 
Hs_G22P1_3 (XRCC6) 5'-GAGGATCATGCTGTTCACCAA-3 
Hs_POLD1_2 5'-CGGGACCAGGGAGAATTAATA-3 
Hs_PRIM1_4 5'-AGCCTTGTAAAGGGTGGTCAA-3 
Hs_RAD51AP1_3 5'-ATGGCATATGTCTCCGATTTA-3 
Hs_RPA3_1 5'-AAGGGAGTAAATCGACCCTCA-3 
Hs_SEPT9_10 5'-CTCAGAGCCCATGGTAACGAA-3 
Hs_XRCC1_4 5'-AAGCCTGAAGTATGTGCTATA-3 
Hs_XRCC5_6 5'-AAGCATAACTATGAGTGTTTA-3 
 
 
2.1.6.2. siRNA Library 
A FlexiPlate siRNA library containing 864 validated siRNAs targeting 288 DNA-repair genes 
in triplicates was purchased from QIAGEN, Hilden, Germany (catalog no. 1027411-385), 
diluted to a stock concentration of 1 µM and stored at -20 °C, according to the Qiagen siRNA 
protocol. 
All 288 DNA-repair genes are listed in 7.1. 
 
2.1.7. Cancerous cell lines 
The following colorectal carcinoma cell lines were used. 
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Table 7: Colorectal cancer cell lines and their culture conditions. 
Cell line Characteristics*  Medium Origin 
 
DLD1 
 
ATCC® CCL-211™ 
Dukes' type C, colorectal 
adenocarcinoma 
 
Standard  
DMEM culture medium 
 
American TypeCulture Collection, 
LGC Standards, Wesel Germany 
 
DLD1 ATR 
 
ATCC® CCL-221™ 
Dukes' type C, colorectal 
adenocarcinoma 
 
Standard 
DMEM culture medium 
 
(97) Gallmeier, Hermann et al. 
(2011) 
 
HCT116 
 
ATCC® CCL-221™ 
Dukes' type C, colorectal 
adenocarcinoma 
 
Standard 
DMEM culture medium 
 
European Collection of Cell Culture, 
Sigma-Aldrich GmbH, Steinheim, 
Germany 
 
HT29 
 
ATCC® HTB-38™ 
Colorectal  
adenocarcinoma 
 
McCoys medium  
+ 10% FCS + 1% P/S 
 
European Collection of Cell Culture, 
Sigma-Aldrich GmbH, Steinheim, 
Germany 
 
LS513 
 
ATCC® CRL2134™ 
Dukes' type C, colorectal 
carcinoma 
 
Standard  
RPMI culture medium 
 
European Collection of Cell Culture, 
Sigma-Aldrich GmbH, Steinheim, 
Germany 
 
RKO 
 
 
ATCC® CRL-2577™ 
Colon carcinoma 
 
Standard  
DMEM culture medium 
 
European Collection of Cell Culture, 
Sigma-Aldrich GmbH, Steinheim, 
Germany 
 
SW480 
 
ATCC® CCL-288™ 
Dukes' type B, colorectal 
adenocarcinoma 
 
Standard  
DMEM culture medium 
 
European Collection of Cell Culture, 
Sigma-Aldrich GmbH, Steinheim, 
Germany 
 
* Reference: American Type Culture Collection ATCC 
 
2.1.8. Cell culture media, buffers and solutions 
Dulbecco´s minimal essential medium  GE Healthcare, PAA Laboratories GmbH, 
(DMEM) high Glucose (4.5 g/l)  Pasching, Austria 
Dulbecco´s PBS (w/o Mg2+, w/o Ca2+) Sigma-Aldrich GmbH, Steinheim, Germany 
Fetal bovine serum Superior (FBS)  Biochrom AG, Berlin, Germany 
OptiMEM® Reduced Serum   Gibco, Life Technologies GmbH 
      Darmstadt, Germany 
RPMI medium     GE Healthcare, PAA Laboratories GmbH, 
      Pasching, Austria 
Trypsin/EDTA (0.25 %/0.02 %  PAA Laboratories GmbH, Pasching, Austria 
 
2.1.8.1. Preparation of cell culture media, buffers and solutions 
Standard DMEM culture medium DMEM 
     10% FCS 
     1% P/S 
     → Stored at 4 °C 
Standard RPMI culture medium RPMI 
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     10% FCS 
     1% P/S 
     → Stored at 4 °C 
 
Freezing medium   Standard DMEM/RPMI culture medium 
     5% DMSO 
 
2.1.8.2. Further preparations of buffers, solutions and gels 
2.1.8.2.1. Preparation of solutions 
BSA solution (1 mg/mL)  10 mg BSA 
     10 mL ddH2O 
     → Stored at -20 °C 
 
Caspase lysis buffer   200 mM HEPES 
     84 mM KCl 
     10 mM MgCl2 
     0.2 mM EDTA 
     0.2 mM EGTA 
     0.5% NP 40 (IGEPAL) 
 
Additionally, the following protease and phosphatase inhibitors were immediately added to 
caspase lysis buffer before usage.  
 
     1 mM PMSF 
     1 mM DTT 
     1 µg/mL Pepstatin 
     5 µg/mL Aprotinin 
 
NaCl solution (5 M)   146.1 g NaCl 
     450 mL ddH2O 
     → Stored at RT 
 
Nicoletti staining solution  228 mg C6H5Na3H7 x 2H2O 
     189 µL Triton X-100 
     10 mL 50 µg/mL propidium iodide 
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PCR loading dye solution (10x) 0.05 g Orange G 
     1.5 g Ficoll® (type 400) 
     1 mL 0.5 M EDTA (pH 8) 
     Add to 10 mL ddH2O 
     → Stored at RT 
 
Resolving gel solution  10 mL 10% SDS 
     250 mL 1.5 M Tris pH 8.8 
     400 mL ddH2O 
     → Stored at 4 °C 
 
SDS solution (10 %)   10 g SDS 
     90 mL ddH2O 
     → Stored at RT 
 
Stacking gel solution   5 mL 10% SDS 
     62.5 mL 1 M Tris pH 6.8 
     → Stored at 4 °C 
 
2.1.8.3. Preparation of buffers 
Blocking buffer    5% (w/v) non-fat milk powder  
     TBST buffer (1x) 
 
p38 protein lysis buffer  40 mg Na4P2O7 
     68 mg NaF 
     440 mg β-Glycerophosphate 
     0.8 mL Triton X-100 
     0.8 mL 100 mM Na3VO4 
     1.6 mL 2 mM EDTA 
     2.4 mL 5 M NaCl 
     16 mL 100 mM Tris Base, pH 7.4 
     → Stored at 4 °C 
 
Additionally, 50 µL of the Protease Inhibitor Cocktail Set 1 (see 2.1.5.3) were immediately 
added to 5 mL of p38 protein lysis buffer before usage.  
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Sample loading buffer   10 mg Bromophenol blue 
(Laemmli buffer, 5x)   1 g SDS 
     2.5 mL SDS-PAGE Stacking gel buffer, pH 6.8 
     2.5 mL β-Mercaptoethanol 
     5 mL Glycerol 
     →Stored at -20 °C 
 
SDS-PAGE electrophoresis  10 g SDS 
running buffer (10x)   30 g Tris Base 
     144 g Glycine 
     Add to 1 l ddH2O 
     → Stored at RT 
 
SDS-PAGE resolving gel buffer 181.7 g 1.5 M Tris Base 
     900 mL ddH2O 
     → Adjust pH to 8.8 and add ddH2O to 1 L. 
     → Stored at RT 
 
SDS-PAGE stacking gel buffer 181.7 g 0.5 M Tris Base 
     900 mL ddH2O 
     → Adjust pH to 6.8 and add ddH2O to 1 L. 
     → Stored at RT 
 
TBS buffer (10x)    24.1 g Tris Base 
     80 g NaCl 
     800 mL ddH2O 
     → Adjust pH to 7.6 and add ddH2O to 1 L. 
     → Stored at RT 
 
TBST buffer (1x)   1 mL Tween20 
     100 mL 10x TBS 
     800 mL ddH2O 
     → Stored at RT 
 
Transfer buffer (10x)   30 g Tris Base 
     144 g Glycine 
     Add to 1 L ddH2O 
     → Stored at RT 
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Transfer buffer (1x)   100 mL 10x Transfer buffer  
     200 mL Methanol  
     700 mL ddH2O 
     → Stored at RT 
 
2.1.8.4. Gels 
Agarose gel (2%)   4 g Agarose 
     200 mL ddH2O 
     → Stored at 4 °C 
 
SDS-PAGE resolving gel (8%) 0.006 mL TEMED 
     0.1 mL 10% Ammonium persulfate 
     0.1 mL 10% SDS 
     2.5 mL 1.5 M Tris (pH 8.8) 
     2.7 mL 30% Acryl-bisacrylamide mix 
     4.6 mL ddH2O 
     → Used directly 
 
SDS-PAGE resolving gel (10%) 0.004 mL TEMED 
     0.1 mL 10% Ammonium persulfate 
     0.1 mL 10% SDS 
     2.5 mL 1.5 M Tris (pH 8.8) 
     3.3 mL 30% Acryl-bisacrylamide mix 
     4.0 mL ddH2O 
     → Used directly 
 
SDS-PAGE stacking gel (5%) 0.005 mL TEMED 
     0.05 mL 10% Ammonium persulfate 
     0.05 mL 10% SDS 
     0.63 mL 1.5 M Tris (pH 6.8) 
     0.83 mL 30% Acryl-bisacrylamide mix 
     3.4 mL ddH2O 
     → Used directly 
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2.1.9. Primer 
The following primers (Metabion international AG, Munich, Germany) were used for 
KAPATaq DNA Polymerase Standard PCR. 
 
Table 8: Primer for KAPATaq DNA Polymerase Standard PCR. 
Primer Target sequence 
 
Forward MycoPrimer 
 
5'-GGGAGCAAACAGGATTAGATACCCT-3' 
Reverse MycoPrimer 5'-TGCACCATCTGTCACTCCGTTAACCTC-3' 
 
 
2.1.10. Standards 
2.1.10.1. Standards for agarose gel electrophoresis 
Low Molecular Weight DNA Ladder   New England Biolabs GmbH,  
       Frankfurt am Main, Germany 
O'GeneRuler™ 1 kb Plus DNA Ladder  Fermentas Life Science, Fisher Scientific 
       GmbH, Schwerte, Germany 
 
2.1.10.2. Standards for SDS-PAGE 
MagicMark™ XP Western Protein Standard Life Technologies, Darmstadt, Germany 
Precision Plus Protein™Standards   Bio-Rad Laboratories, Munich, Germany 
2.1.11. Kits 
Apo-One Homogenous Caspase3 Kit  Promega GmbH, Mannheim, Germany 
KAPATaq PCR Kit KK1015    KapaBiosystems Ltd., London, UK 
 
2.1.12. Consumables 
Adhesive PCR Film     PeQLab Biotechnologies GmbH, 
       Erlangen, Germany 
Cell Scraper (16 cm)     Sarstedt AG & Co. KG,  
       Nümbrecht, Germany 
Cover glass      Fisher Scientific GmbH,  
       Schwerte, Germany 
Cover slips      Thermo Scientific, 
       Langenselbold, Germany 
CryotubesCryo.S™     Greiner Bio-One GmbH, 
       Frickenhausen, Germany 
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Culture dishes (10 cm)    BD Biosciences, San Jose, CA, USA 
Culture plates (6-/96-well plate)   BD Biosciences, San Jose, CA, USA 
Cuvettes      Sarstedt AG & Co. KG,  
       Nümbrecht, Germany 
Gloves       Semperit GmbH, Vienna, Austria 
Microtubes (1.5 mL)     Sarstedt AG & Co. KG,  
       Nümbrecht, Germany 
Microtubes (2 mL)     Eppendorf Vertrieb Deutschland GmbH, 
       Wesseling-Berzdorf, Germany 
Non-pyrogenic serological pipette   Sigma-Aldrich GmbH,  
       Steinheim, Germany 
PARAFILM® M     Sigma-Aldrich GmbH,  
       Steinheim, Germany 
Pasteur pipettes     Brand GmbH, Wertheim, Germany 
PCR soft tubes      Fisher Scientific GmbH,  
       Schwerte, Germany 
Pipette tips      VWR International GmbH,  
       Darmstadt, Germany 
PVDF membranes     Zefa-Laboratories GmbH,  
       Harthausen, Germany 
Ranin tips      Mettler-Toledo, LLC, Columbus, USA 
Sterile filter       PeskeGmbH, Aindling-Pichl, Germany 
Tubes (15/50 mL)     BD Biosciences, San Jose, CA, USA 
X-ray film       Fuji Film Europe GmbH,  
       Düsseldorf, Germany 
 
2.1.13. Instruments 
Accuri C6 Flow Cytometer® (FACS)   BD Biosciences, San Jose, CA, USA  
Airfuge® Air-Driven Ultracentrifuge   Beckman Coulter GmbH,  
       Krefeld, Germany 
Cell counting chamber (0.0025 mm2/ 0.1 mm) Carl Roth GmbH & Co. KG,  
       Karlsruhe, Germany 
Centrifuge ROTANTA    HettichGmbH& Co. KG,  
       Tuttlingen, Germany 
 
Refrigerated centrifuge    Eppendorf Vertrieb Deutschland GmbH,  
       Wesseling-Berzdorf, Germany 
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CytoFluor 4000 plate reader    Per-SeptiveBiosystems,  
       Framingham, MA, USA 
Electrophoresis transfer unit    PeQLab Biotechnologies GmbH, 
       Erlangen, Germany 
Electrophoresis transfer chamber + power supply Bio-Rad Laboratories GmbH,  
       Munich, Germany 
Inverted Fluorescence Microscope Axiovert 135  Carl Zeiss Jena GmbH, Jena, Germany 
HERA cell culture incubator    Fisher Scientific GmbH,  
       Schwerte, Germany 
Laminar Hood      Fisher Scientific GmbH,  
       Schwerte, Germany 
Mini Spin Centrifuge     Eppendorf Vertrieb Deutschland GmbH, 
       Wesseling-Berzdorf, Germany 
Olympus CK2 Inverted Microscope   Olympus Optical Co. GmbH,  
       Planegg, Germany 
PCR cycler      Eppendorf Vertrieb Deutschland GmbH, 
       Wesseling-Berzdorf, Germany 
PCR gel electrophoresis chamber   Bio-Rad Laboratories GmbH,  
       Munich, Germany 
PCR gel electrophoresis chamber power supply Bio-Rad Laboratories GmbH,  
       Munich, Germany 
pH meter      Inolab®-WTW GmbH,  
       Weilheim, Germany 
Pipettes (10/20/200/1000 µL)   Eppendorf Vertrieb Deutschland GmbH, 
       Wesseling-Berzdorf, Germany 
Ranin multichannel pipettes (300 µL)  Mettler-Toledo, LLC, Columbus, USA 
Ranin pipettes (2/10/20/200/1000/2000 µL)  Mettler-Toledo, LLC, Columbus, USA 
Refrigerators (4/-20 °C)    LIEBHERR, Hamburg, Germany 
Thermomixer comfort     Eppendorf Vertrieb Deutschland GmbH, 
       Wesseling-Berzdorf, Germany 
UV/Vis Spectrophotometer Ultraspec 3100 pro Amersham Biosciences,  
       Freiburg, Germany 
Vortex Mixer VM-300     NeoLabMigge, Heidelberg, Germany 
Water bath      Labortechnik Medingen,  
       Arnsdorf, Germany 
Western Blot Gel making unit   Bio-Rad Laboratories GmbH, 
       Munich, Germany 
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2.1.14. Software 
CFlow Plus BD Accuri Software    BD Biosciences, San Jose, CA, USA 
IBM SPSS Statistics 21    SPSS Inc., Chicago, IL, USA 
Microsoft Office 2007/2010    Microsoft, Redmond, WA, USA  
Prism/GraphPad     GraphPad Software Inc.,  
       La Jolla, CA, USA 
Zeiss Axio Vision Rel. 4.8    Carl Zeiss Jena GmbH, Jena, Germany 
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2.2. Methods 
2.2.1. Cell culture methods 
2.2.1.1. Standard cell culture conditions and subculturing 
All cells (see 2.1.7) were grown in standard DMEM/RPMI culture medium (see 2.1.8.1) in a 
humidified incubator under standard culture conditions (37 °C, 5% CO2). Cells were checked 
microscopically to ensure viability and confluence. Cells were assessed regularly for 
mycoplasma contamination by PCR (see 2.2.4). For subculturing, all media, additives, 
buffers and trypsin were preheated before using. Every 2 to 3 days, cells were washed once 
in sterile PBS, trypsinized for an appropriate time at 37 °C and subcultured. 
 
2.2.1.2. Thawing and freezing (cryopreservation) of cells 
Immediately after thawing, cells were added to cold standard DMEM/RPMI culture medium, 
centrifuged (1200 rpm, 10 min, RT) and re-suspended in fresh standard DMEM/RPMI culture 
medium.  
To freeze cells, cell confluence was 80-90%. The cells were washed in PBS and trypsinized. 
After centrifugation (1200 rpm, 10 min, RT) in standard culture media, the cell pellet was 
resuspended in freezing medium, aliquoted in cryovials and stored at -80 °C for 24 h before 
transferring into liquid nitrogen. Cells were periodically frozen to maintain original cell 
conditions. 
 
2.2.1.3. Determination of cell numbers 
The number of cells were determined prior to every experiment in order to maintain equal cell 
amounts required for each experiment. After the cells have been trypsinized and 
resuspended in standard culture medium, a volume of 10 µL of cell suspension was mixed 
with 10 µL trypan blue and analyzed in a cell counting chamber. Cells in 4 quadrates were 
counted. The average cell number was multiplied by 104 to obtain the final cell number 
per mL.  
 
2.2.1.4. Cell cycle analysis by flow cytometry 
Cells were grown in 6-well plates. At 80% confluence, the cells were trypsinized, collected, 
washed with sterilized, ice-cold PBS once and incubated in Nicoletti staining solution (light 
sensitive) according to the method by Nicoletti (98). Quantification of cell cycle distribution 
and subG1-cell fraction were analyzed by flow cytometry and CFlow Plus software. Per 
sample, 20.000 events were analyzed. 
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2.2.2. RNA interference experiments
2.2.2.1. siRNA library transfection
A siRNA library was used containing 288 validated DNA
different siRNAs (QIAGEN, Hilden, Germany)
plates to reach confluence at day
supplementary-free medium with the respective siRNAs 
of 10 nM using Oligofectamin (Invitrogen, Darmstadt, Germany) in OptiMEM (Gibco, Life 
Technologies GmbH, Darmstadt, Germany). 4
was added to the cells. 120 h
0.2% SYBR®Green (Lonza, Cologne, Germany) was added. Fluorescence was measured 
using a CytoFluor Series 4000 plate reader (PerseptiveBiosystems, Framingham, MA, USA) 
(Fig. 4).  
 
 
Figure 4: Experimental procedure of the siRNA library screen.
transfected with 288 DNA-repair genes targeted by three 
 
Four independent siRNA library screens were per
reflecting triplicate wells. The 
treated value by the average of 12 untreated control values for both DLD1 
DLD1 ATRs/s cells. The proliferation
inhibition value of DLD1 parental 
inhibition ratio and the standard 
proliferation inhibition ratio values that each represented triplicates from three different 
oligonucleotides targeting one particular gene. DNA
categories defined as either "
proliferation inhibition. DNA-repair genes were scored as “
the mean growth inhibition ratio was >1.50 and the average relative survival of 
parental cells was >0.45. Gene targets causing comparable growth inhibitions in DL
parental and DLD1 ATRs/s cells were scored as "
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average relative survival of DLD1 parental and DLD1 ATRs/s cells was ≤0.45, respectively, 
calculated by the mean of four individual proliferation inhibition values for each cell line from 
three different oligonucleotides targeting one particular gene. Further, ∆-values of the 
average relative survival of DLD1 parental and DLD1 ATRs/s cells were calculated by 
subtracting the average relative survival of DLD1 parental and DLD1 ATRs/s cells, 
respectively, and scored as "ATR-genotype dependent” DNA-repair genes with ∆-values of 
≥0.3 and "ATR-genotype independent” DNA-repair genes with ∆-values of <0.3. As 
preliminary experiments confirmed no relevant proliferation differences between untreated 
and mock-transfected cells, untreated cells were used as controls in the following screening 
experiments. 
 
2.2.2.2. siRNA oligonucleotide transfection 
Cells at 30-50% confluence were transiently transfected in supplementary-free DMEM/RPMI 
medium using oligofectamin in OptiMEM and siRNA directed against a single gene or a non-
coding sequence of ß-galactosidase (ßGAL) or no siRNA (mock-transfected). siRNAs were 
used at final concentrations of 2.5, 5, 10, 20, 40 and 80 nM. The transfection proceeded for 
4 h before adding serum-containing standard DMEM/RPMI culture medium. After different 
incubation times from 24 to 120 h, protein depletion was either quantified by immunoblotting 
(2.2.5.1) or cell proliferation differences were assessed by quantitative SYBR®Green 
fluorescence measurement (2.2.2.1).  
 
2.2.2.3. Cell proliferation assay 
Cell proliferation assays were performed over a broad range of concentrations covering 
100% to 0% cell survival. 800 to 3,000 cells/well were seeded in 96-well plates to reach 
confluence on day 7. After settling, the cells were incubated with various drugs at multiple 
concentrations. Following incubation for 120 h, the cells were washed with sterilized, ice-cold 
PBS, lysed in 100 µL sterilized ddH2O and 0.2% SYBR®Green was added. Fluorescence 
was measured using a CytoFluor Series 4000 plate reader and proliferation inhibition was 
calculated as compared to the untreated control samples. At least three independent 
experiments were performed per drug, with each data point reflecting triplicate wells. Error 
bars represent standard deviation from three experiments.  
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2.2.3. Molecular biological methods 
2.2.3.1. Detection of Mycoplasma contamination 
PCR technique was used to detect mycoplasma contamination in cell culture supernatants. 
After 72 h incubation, cell culture supernatants were analyzed according to KAPATaq DNA 
Polymerase Standard PCR protocol (Fig. 5) using Forward/Reverse MycoPrimer (see 
2.1.10).  
 
Ingredients 
 
Master Mix (1x) Cycling instructions 
  
Cell culture supernatant 1.0 µL 1.    95 °C 2 min   
KAPA B buffer (10x) 1.0 µL     
dNTP-Mix (1 mM) 0.2 µL 2.    95 °C 30 min   
Forward MycoPrimer 0.1 µL    35 
Reverse MycoPrimer 0.1 µL 3.    62 °C 30 sec  cycles 
DMSO 0.2 µL     
KAPATaq polymerase (5 U/µL) 0.04 µL 4.    72 °C ∞ 40 sec   
ddH2O 7.36 µL     
 10 µL 4.    72 °C ∞ 2 min   
      
  5.    4 °C ∞   
 
Figure 5: KAPATaq Standard PCR protocol. 
 
2.2.4. Biochemical methods 
2.2.4.1. Cell lysate preparation for protein quantification 
Cells were trypsinized and centrifugated (1200 rpm, 10 min, RT). The supernatant was 
discarded and cells were washed with ice-cold PBS twice. After centrifugation (1200 rpm, 
10 min, RT), PBS was removed and the cell pellet was lysed in freshly prepared p38 protein 
lysis buffer including protease inhibitor cocktail Set 1 (Calbiochem, 30 min, on ice). The cell 
pellet was centrifuged (10,000 rpm, 10 min, 4 °C) and the supernatant containing protein 
lysate was stored at -20 °C. 
 
2.2.4.2. Protein quantification 
To adjust similar protein amounts for SDS-PAGE, Bradford protein assay was used to 
measure protein concentrations of lysates according to manufacturer´s recommendations 
(99). Bradford reagent was diluted 1:5 in ddH2O. Afterwards, 1 µL diluted BSA protein 
standard (0.2, 0.4, 0.6, 0.8 mg/mL) or 1 to 5 µL protein lysate were mixed in 1000 µL diluted 
Bradford reagent. The mixture was shortly incubated (5 min, RT) and the absorbance was 
measured at 595 nm wave length at a spectrophotometer. Lysate concentrations were 
calculated on the basis of the linear regression obtained from protein standard values.  
 
MATERIAL AND METHODS 
__________________________________________________________________________ 
- 32 - 
 
2.2.4.3. One dimensional SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was conducted as described previously (100). In short, Laemmli buffer (5x) was 
added to concentration-adjusted lysates. Samples were boiled (10 min, 95 °C), centrifuged 
briefly before separating 20 to 60 µg of cell extracts by SDS-PAGE using 5% (w/v) 
acrylamide stacking gel and 8 to 10% (w/v) acrylamide resolving gel (see 2.1.9.3). Gels were 
run in SDS electrophoresis running buffer (1x) at 80 V for 30 min throughout the stacking gel 
and further 1 h at 120 V.  
2.2.4.4. Fluorometric CASPASE3 activity assay 
Detection of CASPASE3-like DEVDase activity was described previously (101). In short, 
cells were seeded in 96-well plates to reach confluence at day 5 and lysed in caspase lysis 
buffer including protease and phosphatase inhibitors (30 min, on ice). Protein concentration 
was measured by Bradford protein assay as described before. Caspase activity was 
determined from 20 µg protein lysate by incubation with 50 µM of the fluorogenic substrate 
peptide Ac-DEVD-AMC in 200 µL caspase lysis buffer. Cleavage of Ac-DEVD-AMC peptide 
by CASPASE3 releases the fluorophore 7-amino-4-methylcoumarin, which was measured in 
a kinetic assay by spectrofluorometry using an excitation wavelength of 360 nm and an 
emission wavelength of 460 nm. The level of caspase enzymatic activity is directly 
proportional to the fluorescence signal. Caspase activity was determined as slope of the 
resulting linear regression. 
 
2.2.5. Immunological methods 
2.2.5.1. Immunoblotting 
Proteins were transferred onto a PVDF membrane (102) (120 mA, 1 h) using a semi-dry blot 
device in the presence of transfer buffer (1x) for immunoblot analysis. 
 
2.2.5.2. Immunoblot staining and detection 
Blotted membranes were blocked in blocking buffer (1 h, RT) prior to primary antibody 
exposure (o/n, 4 °C) followed by the appropriate secondary antibody incubation (2 h, RT). 
Antibodies were diluted 1:1,000 to 1:10,000 in blocking buffer. Target proteins were identified 
using horseradish peroxidase (HRP) conjugated secondary anti-IgG antibodies and ECL 
Western Blotting Substrate according to the manufacturer´s instructions. Semi-quantitative 
analysis for protein expression levels was performed by densitometry. 
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2.2.5.3. Immunofluorescence microscopy for co-localization analysis 
To study γ-H2AX focus formation, cells were grown on coverslips in 6-well plates. At 60% 
confluence, the cells were irradiated at a dose of 4 Gy using a Mueller RT-250 γ-ray tube 
(200 kV and 10 mA, Thoraeus filter, 1 Gy in 1 min 52 s). Consecutively, treated cells were 
washed with sterilized, ice-cold PBS, fixed in 3.7% formaldehyde (10 min, RT) and methanol 
(1 min, RT). After permeabilization in TBS/0.5% Triton X-100 (10 min, RT) and blocking in 
TBS/2% BSA/0.5% Triton X-100 (30 min, RT), cells were incubated with an anti-ATR (1:200), 
anti-phosphoH2AX (1:200) or anti-POLD1 (1:200) antibody in TBS/2% BSA/0.5% 
Triton X-100 (2 h, RT). Afterwards, the cells were washed with sterilized, ice-cold PBS and 
incubated with their corresponding fluorochrome-conjugated antibodies (1:200, see 2.1.3.2.2) 
in TBS/2% BSA/ 0.5% Triton X-100 (2 h, RT). After washing with sterilized, ice-cold PBS, 
nuclei were counterstained with Hoechst 33258 at 10 µg/mL in TBS/0.5% Triton X-100 (10 
min, RT). Slides were mounted with VECTASHIELD mounting medium and analyzed using a 
Axiovert fluorescence microscope (Zeiss) and the AxioVision Re.4.8 software. Exposure time 
and settings were kept constant for all samples within each experiment.  
For co-localization study, the cells were fixed at 4 h post IR. For foci quantification, 45 and 30 
nuclei were scored for ATR-POLD1 and γ-H2AX-POLD1 co-localization analysis, 
respectively, in one single experiment. Values represent the standard deviation of two 
independent experiments.  
 
2.2.6. Statistical methods 
2.2.6.1. Statistical analysis by SPSS  
All statistical analyses were performed using IBM SPSS Statistics 21. Error bars represent 
standard deviation from at least three experiments. FACS and spatial co-localization data 
were statistically interpreted using a paired Student’s t-test. P-values (**p＜0.01, 
***p＜0.001) were considered statistically significant.  
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3. RESULTS 
3.1. siRNA library screening 
3.1.1. Verification of ATR-
Prior to siRNA library screening on
DLD1 CRC cells, both cell lines were verified on 
identity. DLD1 ATR-deficient cells homozygously harboring the hypomorphic Seckel mutation 
(ATRs/s) have been described previously 
reduced but not absent ATR 
or survival (103). For protein synthesis 
suppression below the detection limit 
ATRs/s cells was further verified functionally through
towards the DNA interstrand crosslinking (ICL) agent mitomycin C (MMC, I
(Fig. 6B), as reported before (103; 105)
 
A 
 
Figure 6: ATR deficiency-induced phenotype in DLD1 
DLD1 parental and DLD1 ATRs/s cells by immunoblotting. 
(MMC) sensitivity of DLD1 parental and 
assay. Error bars represent standard deviation 
representing triplicate wells.  
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of DNA-repair genes 
Seckel phenotype in DLD1 cancer cells. 
 human ATR-proficient DLD1 parental 
the ATR protein level to ensure cell line 
(97; 103; 104). This mutation causes strongly 
protein levels without significant impairment of cel
analysis, immunoblotting demonstrated ATR protein 
in DLD1 ATRs/s cells (Fig. 6A). ATR 
 the confirmation of hypersensitiv
.  
B 
 
CRC cells. (A) ATR protein synthesis was assessed in 
β-ACTIN served as loading control. 
DLD1 ATRs/s cells was assessed at 120 h after treatment by proliferation 
of three independent experiments with each data point 
 
 
and ATR-deficient 
l proliferation 
deficiency of DLD1 
ity 
C50 ratio 3.5-fold) 
 
(B) Mitomycin C 
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3.1.2. siRNA library screening 
and DNA-repair genes in DLD1 cells.
ATR-inhibition has recently been demonstrated to induce the
CRCs (104; 106) but the underlying genetic determinants are still insufficiently defined. 
Therefore, a siRNA library screening approach was conducted using
ATR knock-in model (ATRs/s) of human DLD
lethal interactions between ATR
against 288 DNA-repair genes each targeted by three different siRNAs
experimental screening design is schematically outlined in 
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specifically on DLD1 ATRs/s cells were observed for POLD1 knockdown causing a 9-fold 
proliferation inhibition ratio with an average relative survival of 5% (∆-value = 0.42) at 120 h 
post transfection. A 3-fold proliferation inhibition ratio on DLD1 ATRs/s cells was induced upon 
PRIM1 (∆-value = 0.30), XRCC6 (∆-value = 0.38) and XRCC1 knockdown (∆-value = 0.40) 
with an average relative survival of ≤30% of cells, respectively.  
 
Table 9: Identified ATR genotype-dependent DNA-repair genes. ATR-dependent sensitivity upon siRNA-
mediated DNA-repair gene knockdown was assessed in DLD1 parental and DLD1 ATRs/s cells. Proliferation 
inhibition and the average relative survival of DLD1 parental and DLD1 ATRs/s cells of four independent screens 
were analyzed at 120 h. 
 
Rank 
 
Gene target 
 
 
Proliferation 
inhibition 
ratio * 
 
 
Average 
relative 
survival 
DLD1 
 
Average 
relative 
survival 
DLD1 ATRs/s 
∆-value 
Average  
relative  
survival of DLD1 
to DLD1 ATRs/s ** 
 
1 
 
POLD1 
 
9.04±1.42 
 
0.47 
 
0.05 
 
0.42 
2 PRIM1 3.43±1.15 0.47 0.17 0.30 
3 XRCC6 (Ku70) 3.34±0.23 0.68 0.30 0.38 
4 XRCC1 3.03±0.12 0.60 0.20 0.40 
5 SEPT9 1.74±0.11 0.73 0.42 0.31 
6 XRCC5 (Ku80) 1.66±0.12 0.64 0.38 0.26 
 
* The proliferation inhibition ratio was calculated by dividing the proliferation inhibition value of DLD1 parental by 
the value of DLD1 ATRs/s cells. The mean proliferation inhibition ratio and standard error of the mean were 
determined from four individual proliferation inhibition ratio values that each represent triplicates from three 
different oligonucleotides targeting one particular gene. 
** ∆-values of the average relative survival of DLD1 parental and DLD1 ATRs/s cells were calculated by 
subtracting the average relative survival of DLD1 parental and DLD1 ATRs/s cells, respectively. 
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3.1.3. ATR-genotype independent DNA-repair gene knockdown-induced detrimental 
effects on DLD1 cells. 
The DNA-repair gene siRNA library screen identified potential synthetic lethal interactions 
between ATR and DNA-repair genes (Table 9). In addition, ATR-genotype independent 
DNA-repair gene knockdown-induced detrimental effects were identified (Table 10). 
 
Table 10: Identified ATR genotype-independent DNA-repair genes. ATR-independent sensitivity upon siRNA-
mediated DNA-repair gene knockdown was assessed in DLD1 parental and DLD1 ATRs/s cells. Proliferation 
inhibition and the average relative survival of DLD1 parental and DLD1 ATRs/s cells of four independent screens 
were analyzed at 120 h.  
 
Rank 
 
 
 
 
Gene target 
 
 
 
 
 
Proliferation 
inhibition  
ratio* 
 
 
Average 
 
relative 
 
survival 
 
DLD1 
 
Average 
 relative
 
 survival  
DLD1 ATRs/s 
 
Average 
relative  
survival of 
DLD1 and DLD1 
 ATRs/s** 
I∆I 
Average  
relative  
survival of  
DLD1 to DLD1 
ATRs/s*** 
 
1  XAB2  1.40±0.46  0.06 0.05 0.06  0.01  
2  PLK1  2.51±1.86  0.12 0.03 0.08  0.09  
3  RPL35  0.58±0.17  0.07 0.14 0.11  0.07  
4  PSMC4 (TBP7)  1.73±1.14  0.16 0.11 0.14  0.05  
5  RPL27  0.21±0.07  0.04 0.23 0.14  0.19  
6  NUP205  2.85±2.29  0.18 0.15 0.17  0.03  
7  RRM1  1.75±1.04  0.22 0.11 0.17  0.11  
8  POLE  1.63±0.80  0.22 0.12 0.17  0.10  
9  RRM2  1.40±0.39  0.23 0.15 0.19  0.08  
10  PSMA1  0.61±0.24  0.27 0.11 0.19 0.16 
11  POLA1  1.66±1.13  0.22 0.18 0.20  0.04  
12  RPA2 (RPA32)  1.68±0.32  0.26 0.15 0.21  0.11  
13  RPA1 (RPA70)  0.93±0.34  0.22 0.21 0.22  0.01  
14  SNRPF (SMF)  1.06±0.63  0.23 0.21 0.22  0.02  
15  ENDOV  0.74±0.10  0.24 0.35 0.30  0.11  
16  FBXO18 (FBH1)  0.85±0.21  0.27 0.35 0.31  0.08  
17  PMS2P5  1.66±1.02  0.41 0.20 0.31  0.21  
18  PARP4 (VPARP)  1.60±0.62  0.40 0.23 0.32  0.17  
19  FEN1  0.70±0.17  0.28 0.41 0.35  0.13  
20 
  
PCNA  
 
1.83±1.00 
 
 
0.45 
 
0.25 
 
0.35 
  
0.20 
 
* The proliferation inhibition ratio was calculated by dividing the proliferation inhibition value of DLD1 parental by 
the value of DLD1 ATRs/s cells. The mean proliferation inhibition ratio and standard error of the mean were 
determined from four individual proliferation inhibition ratio values that each represent triplicates from three 
different oligonucleotides targeting one particular gene.  
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** The average relative survival of DLD1 parental and DLD1 ATRs/s cells, respectively, was calculated by the 
mean of four individual growth inhibition values for each cell line from three different oligonucleotides targeting 
one particular gene. 
*** ∆-values of the average relative survival of DLD1 parental and DLD1 ATRs/s cells were calculated by 
subtracting the average relative survival of DLD1 parental and DLD1 ATRs/s cells, respectively. 
 
These DNA-repair genes were scored as ATR-genotype independent hits if the average 
relative survival of DLD1 parental and DLD1 ATRs/s cells was ≤0.45 and ∆-values of the 
average relative survival of DLD1 parental and DLD1 ATRs/s cells were low (<0.3) at 120 h 
post transfection. siRNA-mediated knockdown of XAB2 caused a virtually complete loss of 
proliferation shown in an average relative survival in both DLD1 parental and DLD1 ATRs/s 
cells of <10% (∆-value = 0.01). siRNA-mediated knockdown of PLK1 and RPL35 displayed 
an average relative survival in both DLD1 parental and DLD1 ATRs/s cells of <15% 
(∆-value = 0.09/0.07). The results indicate that these genes execute essential functions at 
least in DLD1 CRC cells. 
 
These ATR-genotype independent effects were not the focus of this study. Consequently, 
these DNA-repair genes were not further examined.  
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In summary, the siRNA screen of 288 DNA-repair genes identified potential knockdown-
induced synthetic lethal interactions of POLD1, PRIM1, XRCC6, XRCC1, SEPT9 and 
XRCC5 in DLD1 ATRs/s cells (Table 9). Dose titration experiments confirmed siRNA-
mediated gene knockdown effects of POLD1, PRIM1, XRCC6, XRCC1 and XRCC5 on 
proliferation in DLD1 ATRs/s cells (Fig. 8).  
However, the strongest effect specifically on DLD1 ATRs/s cells was observed and confirmed 
for POLD1 knockdown. Therefore, POLD1 was primarily picked for a more detailed analysis 
in the following experiments.   
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3.2.2. POLD1 knockdown-mediated sensitivity towards chemical inhibition of the 
ATR/CHK1-axis. 
Targeting ATR is a promising strategy in cancer therapy but the majority of ATR-inhibitors is 
currently still in pharmacological development (33; 34; 36; 38; 39; 107; 108). Targeting ATRs' 
major downstream kinase CHK1 might therefore represent a more attractive approach as 
CHK1-inhibitors already undergo clinical trials (109-111). 
Thus, it was analyzed whether siPOLD1-mediated effects in DLD1 ATRs/s cells were similarly 
chemically reproducible through chemical inhibition of ATR as well as CHK1 in DLD1 
parental cells. Various ATR (NU6027, VE-822)- and CHK1 (UCN-01, LY2603618)-inhibitors 
were applied in cell proliferation assays to analyze proliferation differences between POLD1-
depleted and mock-transfected DLD1 parental cells. Targeting ATR with NU6027 was 
reported to sensitize different cancer cells to DNA damaging agents (36). The ATR-inhibitor 
VE-822, a more potent analogue of VE-821 (33; 108), is the first ATR-targeting drug entering 
clinical development (ClinicalTrials.gov: NCT02157792). The CHK1-inhibitors UCN-01 and 
LY2603618 were chosen because their application were already tested in different cancer 
identities, e.g. pancreatic and lung cancer, of phase 2 clinical trials (ClinicalTrials.gov: 
NCT00045747, NCT00072189, NCT00082017, NCT01296568, NCT00988858). 
Upon POLD1 knockdown, a significant hypersensitivity towards NU6027 (IC50 ratio 4-fold), 
VE-822 (IC50 ratio 5-fold) and UCN-01 (IC50 ratio 8-fold) was observed in POLD1-depleted 
but not in mock-transfected and control DLD1 parental cells at 120 h (Fig. 10A).  
To exclude a general unspecific hypersensitivity phenotype upon POLD1 knockdown, 
POLD1-depleted, mock-transfected and control DLD1 parental cells were treated with 
commonly used chemotherapeutics including ICL- and non-ICL-chemotherapeutics (MMC, 
oxaliplatin, 5-fluorouracil (5-FU)). No significant proliferation differences between 
POLD1-depleted, mock-transfected and control DLD1 parental cells were detected upon 
treatment with any of these agents (Fig. 10B).  
  
__________________________________________________________________________
 
A 
 
 
 
 
 
B 
 
 
 
 
 
Figure 10: ATR-/CHK1-dependent proliferation inhibition upon 
Effects on proliferation of (A) ATR-
120 h after treatment in control, mock
bars represent standard deviation of three independent experiments with each data point representing triplicate 
wells. 
RESULTS 
- 43 - 
  
  
 
POLD1 knockdown in DLD1 cancer cells.
 and CHK1-inhibitors or (B) common chemotherapeutics
-transfected or siPOLD1-transfected (10  nM) DLD1 parental cells. Error 
 
 
 
 
 were assessed at 
RESULTS 
__________________________________________________________________________ 
- 44 - 
 
3.2.3. POLD1 knockdown-mediated apoptosis in DLD1 ATRs/s cells. 
The DNA-repair siRNA screen identified detrimental effects on proliferation upon POLD1 
knockdown in DLD1 ATRs/s cells. Furthermore, POLD1-depleted DLD1 parental cells showed 
hypersensitivity towards chemical inhibition with ATR- and CHK1-targeting drugs.  
To elucidate the mechanism underlying the identified synthetic lethal interaction of ATR with 
POLD1, cell cycle distribution and sub-G1 cell fraction were assessed upon siPOLD1 
transfection (10 nM) by flow cytometry in DLD1 ATRs/s versus DLD1 parental cells in a time-
dependent manner. The experimental set-up is schematically depicted in Fig. 11A. No 
significant baseline differences in cell cycle profiles or sub-G1 content were depicted among 
siPOLD1-transfected, mock-transfected and control DLD1 parental cells up to 72 h 
(Fig. 11B). In contrast, DLD1 ATRs/s but not DLD1 parental cells displayed a slightly 
increased sub-G1 fraction at 96 h post siPOLD1-transfection (10%, Fig. 11B), which strongly 
and exclusively increased at 120 h (40%, Fig. 11C-D) indicating an induction of cell death 
mechanisms. 
The two major types of cell death are apoptosis and necrosis, both morphologically 
distinguishable. Apoptosis is characterized by cell shrinkage with an intact plasma 
membrane, chromatin condensation and nuclear fragmentation. The cytoplasm retains in 
membrane-bounded apoptotic bodies (112). On the contrary, necrotic cells swell, the plasma 
membrane is disrupted and cytoplasm release follows (112; 113). With regard to 
morphological changes, an obvious cell shrinkage (Fig. 12A, left panel) along with 
chromatin condensation and apoptotic body formation (Fig. 12A, right panel) were observed 
for POLD1-depleted but not control DLD1 ATRs/s cells indicating a POLD1 
knockdown-mediated apoptosis induction in DLD1 ATRs/s cells.  
To validate and confirm POLD1 knockdown-induced apoptosis, suggested by the increased 
subG1-fraction in the cell cycle experiments and morphological changes in light and 
fluorescence microscopy observations, apoptosis-involved caspases were analyzed. A 
general apoptosis activation is indicated by cleaved Poly (ADP-ribose) polymerase (PARP) 
as well as the initiator caspases CASPASE8, CASPASE9 and the central effector 
CASPASE3. (112) Thus, these proteins were assessed on protein level in DLD1 ATRs/s 
versus DLD1 parental cells upon siPOLD1 transfection (10 nM). Consistently, a cleavage of 
PARP, CASPASE3 and CASPASE9 but not CASPASE8 was selectively observed in DLD1 
ATRs/s but not in DLD1 parental cells upon POLD1 knockdown (Fig. 12B). 
To show that the extrinsic apoptotic pathway is inducible in DLD1 parental and DLD1 ATRs/s 
cells, the tumor necrosis factor α (TNFα) and actinomycin D (AcD) were applied. TNFα as 
corresponding ligand of TNF receptor 1 (TNFR1) triggers extrinsic apoptosis induction 
through initiator CASPASE8 activation (114). A synergistic toxic effect of TNFα and AcD, a 
pro-apoptotic drug, sensitizes cells to TNFα-mediated apoptosis (115). In concordance with  
__________________________________________________________________________
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these data, application of TNFα and AcD activates extrinsic apoptosis in DLD1 parental and 
DLD1 ATRs/s cells, as illustrated by CASPASE8 cleavage (Fig. 12C, upper panel).  
To show that the intrinsic apoptotic pathway is inducible in DLD1 parental and DLD1 ATRs/s 
cells, CASPASE9 activation was analyzed upon irradiation (IR) and etoposide treatment in 
both cells. An IR-induced CASPASE9 activation was shown at 20 Gy in DLD1 parental and 
DLD1 ATRs/s cells (Fig. 12C, middle panel). In addition, etoposide-induced CASPASE9 
activity was detected (Fig. 12C, lower panel), as described before (116). 
Caspase cascade activity was further verified by CASPASE3-dependent cleavage of the 
fluorogenic CASPASE3-specific substrate Ac-DEVD-AMC in DLD1 ATRs/s versus DLD1 
parental control cells at 96 h post siPOLD1 transfection. POLD1-depleted DLD1 ATRs/s cells 
exhibited a 6-fold increase in DEVDase activity, corresponding to CASPASE3 activity, 
compared to DLD1 parental cells (Fig. 12D). 
These data suggest that DLD1 cancer cells with depletion of ATR and POLD1 undergo cell 
death through apoptosis. 
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3.2.4. Effects of combined POLD1- and ATR-depletion on H2AX phosphorylation in 
DLD1 cancer cells upon genotoxic stress. 
DLD1 ATRs/s cells undergo apoptosis upon POLD1 knockdown. To clarify the underlying 
mechanisms, DNA damage- and DNA-repair kinetics were assessed using intranuclear 
γ-H2AX focus formation, elimination and pan-nuclear staining as surrogate markers. The 
spotted phosphorylation of H2AX at Ser-139 to γ-H2AX illustrates one of the earliest 
response events at sites of DNA double-strand breaks (41; 117; 118) formed as 
consequence of irradiation or chemotherapeutic agents (119). In contrast, pan-nuclear 
staining is defined as diffuse phosphorylation of H2AX in the whole nucleus and indicates 
replication stress (41). Experimentally, ATR and POLD1 were down-regulated in DLD1 
parental and DLD1 ATRs/s cells, either alone or in combination. Both cells were additionally 
treated with ionizing gamma-radiation (IR), etoposide or left untreated. 
 
3.2.4.1. POLD1 and ATR depletion-induced γ-H2AX focus formation upon IR-stress.  
After verification of an effective siRNA-mediated POLD1 knockdown at 96 h post transfection 
(Fig. 9C), DLD1 parental and DLD1 ATRs/s cells with or without POLD1 knockdown were 
treated with IR at a sub-lethal dose of 4 Gy or left untreated (experimental set-up 
schematically depicted in Fig. 13A). The sub-lethal dose of 4 Gy was defined using a dose 
titration study (data not shown). Subsequently, γ-H2AX focus formation, elimination and 
pan-nuclear staining were quantified at multiple time points ranging from 0.5 to 120 h. 
Control DLD1 parental and DLD1 ATRs/s cells displayed no significant γ-H2AX focus 
formation or pan-nuclear staining. Upon POLD1 knockdown, a fraction of DLD1 parental cells 
exhibited increased γ-H2AX focus formation (21% of cells showing >10 foci/cell), whereas no 
significant pan-nuclear staining was observed. In contrast, DLD1 ATRs/s cells displayed a 
large fraction of cells that exhibited either an increased γ-H2AX focus formation (36% of cells 
showing >10 foci/cell) or high levels of pan-nuclear staining (36% of cells) upon POLD1 
knockdown (Fig. 13B+C). In general, distinct γ-H2AX foci are rapidly formed within minutes, 
peak at 0.5 to 1 h and recover within 24 h in response to IR (120; 121). Upon treatment with 
IR, a large fraction of γ-H2AX foci-positive cells was expectedly observed at 0.5 h for control 
(63% of cells showing >10 foci/cell) and POLD1-depleted DLD1 parental cells (65%) and an 
even higher fraction for control and POLD1-depleted DLD1 ATRs/s cells (approximately 90%), 
which is consistent with the known ATR deficiency-mediated radio-sensitivity (33). However, 
POLD1-depleted DLD1 ATRs/s cells additionally exhibited an increased fraction of H2AX-
positive cells also at 24 h and even at 120 h after IR, including cells with increased γ-H2AX 
focus formation (63% at 24 h / 41% at 120 h) and pan-nuclear staining (23% at 24 h /7% at 
120 h) (Fig. 13D+E). 
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3.2.4.2. POLD1 and ATR depletion-induced γ-H2AX focus formation upon etoposide  
DNA damage and repair were further examined upon etoposide treatment in POLD1- and 
ATR-deficient DLD1 parental and DLD1 ATRs/s cells. The etoposide concentration used was 
determined by dose titrations using FACS analysis in DLD1 parental and DLD1 ATRs/s cells. 
A sub-lethal dose of 0.25 µM etoposide was defined displaying no cell cycle phase 
alterations at 24 h post treatment in both cells (data not shown).  
The experimental set-up was based on previous experiments (see 3.2.4.1) and is 
schematically depicted in Fig. 14A. Efficient siRNA-mediated POLD1 down-regulation was 
verified (Fig. 9C). As shown before, POLD1-knockdown induced detrimental DNA damage 
was confirmed in DLD1 parental and DLD1 ATRs/s cells persistently showing γ-H2AX focus 
formation (29%/41% of cells showing >10 foci/cell) and occasional pan-nuclear staining 
(4%/7%) at 24 h (Fig. 14B+C), compared to their untreated controls (Fig. 14B).  
Etoposide inhibits topoisomerase II activity eliciting DNA DSBs, which rapidly triggers H2AX 
phosphorylation (122). In response to etoposide treatment, a low level of γ-H2AX was 
displayed at 24 h in DLD1 parental (9% of cells showing >10 foci/cell) and an increased 
fraction of γ-H2AX in POLD1-depleted DLD1 parental and DLD1 ATRs/s cells (27%/34% of 
cells showing >10 foci/cell). Of note, virtually no DNA damage in these three cell lines was 
detectable at 120 h, indicating an efficient DNA repair system. In contrast, POLD1-depleted 
DLD1 ATRs/s cells exhibited an elevated fraction of H2AX-positive cells at 24 h and even at 
120 h after etoposide treatment, displayed by cells with γ-H2AX focus formation (30% at 
24 h/48% at 72 h/42% at 120 h), pan-nuclear staining (13% at 24 h/16% at 72 h/9% at 120 h) 
along with apoptotic body formation (Fig. 14D+E). 
In conclusion, massive DNA damage induced by concomitant depletion of ATR and POLD1 
was confirmed in DLD1 cells. Furthermore, IR, referred to paragraph 3.2.4.1, and etoposide 
treatment similarly elicited detrimental and sustained DNA damage with an impaired or at 
least decelerated DNA-repair machinery specifically in cells with combined ATR- and 
POLD1-defects, as compared to control cells and cells harboring only one of these defects. 
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Figure 13: ATR and POLD1 knockdown-dependent γ-H2AX formation upon IR stress (see page 49). DLD1 
parental and DLD1 ATRs/s cells were grown on coverslips, treated with siPOLD1 at 10 nM or left untreated, then 
irradiated (4 Gy) and stained with an anti-γ-H2AX antibody (green). Nuclei were counterstained with 
Hoechst 33258 (blue).(A) Timeline depicting experimental procedure. (B+D) Representative fluorescence images 
and (C+E) γ-H2AX quantification of control versus siPOLD1-treated DLD1 parental and DLD1 ATRs/s cells, 
respectively, are shown (B+C) at 120 h after transfection without irradiation and (D+E) upon irradiation at 0.5 h, 
24 h and 120 h. Arrows indicate pan-nuclear γ-H2AX staining. A scale bar (10 µm) is depicted. (C+D) For 
quantification, at least 50 cells of each cell line and condition were scored in two independent experiments. Error 
bars represent standard deviation of two experiments. 
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3.2.5. IR-induced co-localization of POLD1 with ATR and γ-H2AX. 
To test whether ATR and POLD1 co-localize at sites of DNA damage, spatial localization of 
ATR, POLD1 and γ-H2AX was assessed upon IR stress, using co-immunostaining analysis. 
DLD1 parental cells were irradiated at 4 Gy and POLD1, ATR and γ-H2AX localization were 
examined by fluorescence microscopy at 4 h post IR using fluorescence-coupled antibodies 
directed against the targeted proteins. Co-localization of ATR and POLD1 was depicted in 
cell nucleus partially in untreated DLD1 parental cells (2.9 ± 1.6 co-localized foci) and with a 
9.7-fold increase of spatial overlap (27.6 ± 8.9 co-localized foci) upon IR (Fig. 15A+C,D). 
Further, POLD1 relocalization to sites of DNA damage visualized by γ-H2AX focus formation 
was assessed upon irradiation. POLD1 clearly co-localized with γ-H2AX foci with a 14.2-fold 
increase in irradiated DLD1 parental cells (9.0 ± 2.3 co-localized foci) in comparison to 
untreated DLD1 parental cells (0.6 ± 0.2 co-localized foci) as illustrated by yellow-colored foci 
(Fig. 15B+C,D). 
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Figure 14: ATR and POLD1 knockdown-dependent γ-H2AX formation upon etoposide stress (see 
page 51). DLD1 parental and DLD1 ATRs/s cells were grown on coverslips, treated with siPOLD1 at 10 nM or left 
untreated, then treated with etoposide (0,25 µM) and stained with an anti-γ-H2AX antibody (green). Nuclei were 
counterstained with Hoechst 33258 (blue).(A) Timeline depicting experimental procedure. (B+D) Representative 
fluorescence images and (C+E) γ-H2AX quantification of control versus siPOLD1-treated DLD1 parental and 
DLD1 ATRs/s cells, respectively, are shown (B+C) at 120 h after transfection without etoposide and (D+E) upon 
etoposide treatment  at 24 h, 72 h and 120 h. Thin arrows indicate pan-nuclear γ-H2AX staining, thick arrows 
apoptotic bodies. A scale bar (10 µm) is depicted. (C+D) For quantification, at least 50 cells of each cell line and 
condition were scored in two independent experiments. Error bars represent standard deviation of two 
experiments.   
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4. DISCUSSION 
In response to DNA damage and replication stress, ATR acts as a central checkpoint 
regulator and mediator of the DNA-repair machinery by homologous recombination (4). ATR-
inhibition has recently been demonstrated to induce the elimination of tumor cells in CRCs 
(104; 106) but the underlying genetic determinants are still insufficiently defined. Using a 
well-defined genetic ATR knock-in model of human CRC cells (97), a siRNA library screening 
approach was conducted to identify potential synthetically lethal interactions between ATR 
and DNA-repair genes. Six DNA-repair genes exhibiting synthetically lethal interactions with 
ATR and 20 genes displaying ATR genotype-independent knockdown-induced cell killing 
were identified. Among the identified genes exhibiting synthetically lethal interactions with 
ATR, the most profound effects were observed for POLD1 and were further characterized.  
 
4.1. DLD1 ATRs/s cells as ideally-suited model for DNA-repair 
siRNA library screening 
ATR is an essential gene (126) and consequently, few cellular models exist to investigate its 
complete disruption. However, the bi-allelic hypomorphic ATR splice site mutation 2101A→G, 
naturally found in Seckel syndrome patients (29), results in a subtotal ATR protein depletion 
without significant effects on cancer cell growth or viability (97). The human CRC line DLD1 
engineered to homozygously harbor this mutation (termed ATRs/s cells) (97; 104; 127) thus 
represents an ideally-suited model system for our question, as subtotal ATR protein 
depletion likely mimics the incomplete inhibition of ATR achievable through pharmacological 
means more closely than the complete and in most instances lethal ATR gene knockout 
(126). Preliminary experiments confirmed that DLD1 ATRs/s cells display suppression of ATR 
protein below the detection limit of our assay as well as increased sensitivity towards MMC, 
as previously described (97; 103). 
In this screen, 26 out of 288 DNA-repair genes were identified, whose knockdown elicited 
either selective ATR genotype-dependent or -independent detrimental effects. Hit rates did 
not systematically differ between DLD1 parental and DLD1 ATRs/s cells (hit rate = 9%) ruling 
out the systematic error of a general siRNA-transfection-mediated cell killing of DLD1 ATRs/s 
cells. In addition, the screening validity was confirmed by a z factor of >0.5 (128). The 
sensitivity of this approach was illustrated by the re-identification of the previously described 
synthetically lethal interactions of XRCC1 or PRIM1 with ATR (50; 129). In addition, very 
recent data published during the writing of this PhD thesis confirmed some of the hits 
obtained in our genetic ATR model including especially POLD1 and PRIM1 (130). Mohni and 
colleagues used a less ATR-specific synthetic lethal screening system applying the 
ATR-inhibitor VE-821. VE-821 was described as less specific than its further developed 
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analogue VE-822 showing elevated potency, less cell and tissue toxicity and improved 
pharmacokinetic features (33). VE-822 was used in our study for pharmacological 
reproduction of synthetic lethal interactions of ATR with POLD1. Further, siRNA-library 
screening was conducted in a well-defined ATR knock-in model excluding unspecific inhibitor 
side effects as well as ensuring that effects specifically results from ATR protein depletion. 
While Mohni et al. described synthetically lethal effects only in one cell line (U2OS bone 
osteosarcoma cells) (130), our study provides data on the specific killing of cells harboring 
ATR and POLD1 deficiency in several CRC cell lines along with different ATR- and CHK1-
inhibitors (Fig. 10, Fig 17) confirming our screening data. 
 
4.2. ATR genotype-independent effects in DLD1 cancer cells 
Our screen identified 20 DNA-repair genes (Table 10), whose knockdown led to proliferation 
inhibition in DLD1 parental and DLD1 ATRs/s cells independently of ATR status (hit rate = 7%) 
indicating essential functions of these genes at least in DLD1 cells. The strongest ATR 
genotype-independent effects were observed for XAB2 and PLK1 knockdown, both of which 
resulted in a virtually complete proliferation loss. Consistently, homozygous XAB2 and PLK1 
knockout mice display an early embryonic lethal phenotype (131; 132) and knockdown of 
XAB2 was reported to induce widespread cell death in human bladder, cervix and pancreatic 
cancer (133). However, these ATR-genotype independent effects were not the focus of this 
study. Consequently, these DNA-repair genes were not further examined. 
 
4.3. ATR genotype-dependent effects identified synthetic lethal 
interactions with DNA-repair genes in DLD1 cancer cells 
Five genes interplaying in DNA repair as well as in DNA replication at the DNA replication 
fork were identified, whose knockdown led to proliferation inhibition selectively of DLD1 
ATRs/s but not of DLD1 parental cells (hit rate = 2%) (Table 9, Fig. 19). The strongest effects 
selectively on DLD1 ATRs/s cells were observed for POLD1 and PRIM1 knockdown, both of 
which are involved in DNA repair or DNA replication synthesis (134; 135). POLD1 was 
further characterized as described below. PRIM1 encodes the catalytic subunit of DNA 
primase synthesizing short RNA primers, which are extended in complex with DNA 
polymerase α (136). A polymerase switch to DNA polymerase δ harboring the catalytic and 
proofreading subunit POLD1 ensures primer elongation and DNA strand polymerization. 
Accordingly, both proteins, PRIM1 and POLD1, are involved in immediately consecutive DNA 
replication steps (137) explaining the synthetically lethal effects upon depletion of either 
protein in DLD1 ATRs/s cells. Mechanistically, RNA primer synthesis influences 
replication-dependent binding of ATR to chromatin, which is required for checkpoint 
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4.4. Pharmacological reproduction of the synthetic lethal 
interaction between ATR and POLD1 
Additional studies are required to confirm and mechanistically characterize the synthetic 
lethal interactions between ATR and the DNA-repair genes identified in this study. As a start, 
POLD1 was picked for in-depth characterization, as its knockdown elicited by far the 
strongest effects in DLD1 ATRs/s cells. After confirmation of time- and siPOLD1 
concentration-dependent cell killing specifically of DLD1 ATRs/s cells, these effects were 
demonstrated to be pharmacologically reproducible by using chemical ATR-inhibitors on 
POLD1-depleted DLD1 parental cells. Importantly, a general hypersensitivity phenotype of 
POLD1-depleted DLD1 parental cells was excluded by treatment with various 
chemotherapeutics including ICL- and non-ICL-agents, none of which elicited POLD1-
dependent hypersensitivity. Clonally selected heterozygous DLD1 ATR+/s cells remained 
unaffected by POLD1 depletion excluding artefacts due to clonal variability. 
Intracellular protection against DNA damage and replication stress is mediated by both ATR 
and its major downstream effector kinase CHK1. Both proteins are essential and appear to 
similarly promote tumorigenesis (28; 126; 143). As CHK1-inhibitors are currently further 
developed than ATR-inhibitors (144) and already undergoing testing in clinical trials (145), 
we analyzed whether the effects of ATR-inhibition could similarly be induced by targeting 
CHK1. The CHK1-inhibitor UCN-01 was applied for this purpose despite its rather low 
selectivity because it currently represents the only FDA-approved CHK1-inhibitor (145). 
Indeed, the inhibition of CHK1 by UCN-01 caused similar effects on POLD1-depleted DLD1 
parental cells as ATR-inhibition did. Nevertheless, inhibition of ATR as the upstream kinase 
of CHK1 is expected to potentially elicit additional effects as compared to the specific 
inhibition of CHK1, as multiple other substrates are canonically phosphorylated by ATR in 
various tumor identities (5; 104; 146). Concomitantly, kinases other than ATR have been 
demonstrated to mediate compensatory ATR-independent CHK1 activation (147). 
Consistently, ATR and CHK1 have been demonstrated to not function completely 
epistatically (148) and thus, ATR-inhibitors and CHK1-inhibitors are expected to not be 
readily interchangeable for cancer-therapeutic approaches. 
In an effort to generalize these data beyond one single cell line, the effects of ATR- and 
CHK1-inhibitors were investigated in a panel of CRC cell lines including lines exhibiting a 
microsatellite instable (MSI) as well as those exhibiting a chromosomal instable (CIN) pheno-
type (125; 149). POLD1-depleted RKO, SW480 and LS513 cells displayed increased 
sensitivity towards ATR-/CHK1-inhibitors as compared to control cells.  
Considering that siRNA-mediated POLD1 knockdown was exclusively done once prior to 
inhibitor treatment, POLD1 knockdown at multiple time points might further increase ATR- 
and CHK1-inhibitor effects in all cell lines. The fact that only some but not all ATR-/CHK1-
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inhibitors elicited POLD1-dependent effects might be ascribable to the additional unspecific 
inhibition of other targets inherent to chemical inhibitors along with the heterogeneous 
genotype of the tested CRC lines. Nevertheless, inhibition of the ATR/CHK1-axis could be a 
generalizable therapeutic concept in patients with POLD1 low-or non-expressing tumors.  
 
4.5. Mechanistic characterization of the synthetic lethal 
interaction between ATR and POLD1 
To investigate the underlying mechanism of the synthetic lethal interaction between ATR and 
POLD1, cell cycle distribution was analyzed to detect cell cycle arrests along with the sub-G1 
fraction as a surrogate marker for apoptosis. While no significant effects on cell cycle were 
observed, a significantly increased sub-G1 fraction was displayed in DLD1 ATRs/s cells upon 
POLD1 knockdown. Apoptosis was further confirmed by the proteolytic cleavages of PARP, 
the initiator CASPASE9 and the executioner CASPASE3 (150) as well as by CASPASE3-
attributable DEVDase activity (101). In general, these data are consistent with previous 
studies showing spontaneous apoptosis in vivo in POLD1-/- mice (151). More specifically, 
POLD1 down-regulation has been demonstrated to mediate the reduction of DNA synthesis 
in vitro (152), which is expected to activate the DNA replication checkpoint (153). Disruption 
of this checkpoint by ATR deficiency might thus prevent cell cycle arrest in S-phase, a 
hypothesis supported by the absence of cell cycle disturbances in our experiments. Taken 
together, reduction of DNA synthesis caused by POLD1 knockdown along with premature 
entry into mitosis caused by ATR deficiency provides a plausible mechanism for the 
apoptosis-mediated synthetic lethality of POLD1 and ATR in our experiments. 
Since POLD1 represents a DNA polymerase δ subunit with critical catalytic and proofreading 
activity in replicative DNA synthesis, recombination and especially repair processes (134), 
the effects of POLD1 depletion on DNA damage- and DNA repair-kinetics in DLD1 parental 
and DLD1 ATRs/s cells were investigated. Upon POLD1 knockdown, DLD1 ATRs/s cells but 
not DLD1 parental cells displayed strongly increased levels of endogenous DNA DSBs, as 
illustrated by increased nuclear γ-H2AX focus formation (118). Upon exogenously induced 
DNA DSBs by IR or etoposide, sustained γ-H2AX focus accumulation (˃120 h) was observed 
specifically in siPOLD1-transfected DLD1 ATRs/s cells but not in control DLD1 ATRs/s cells or 
control or siPOLD1-transfected DLD1 parental cells, strongly supporting an impaired or at 
least decelerated DNA-repair capacity. These data further support our above hypothesis that 
depletion of POLD1 causing increased DNA-damage (152) and decreased DNA-repair in 
combination with deficient ATR-signaling causing DNA replication checkpoint disruption 
(153), premature entry into mitosis and eventually apoptosis mechanistically explains the 
synthetic lethality of these two genes.  
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Co-localization studies in DLD1 parental cells supported the existence of a synthetic lethal 
interaction of ATR with POLD1 in the presence of DNA damage/repair. POLD1 relocalization 
to sites of DNA damage visualized by γ-H2AX focus formation was displayed upon IR. 
Consistently, POLD1 recruitment with γ-H2AX after exposure to UV was reported to almost 
100% confirming our data (154). In concordance with the observed spatial overlap of ATR 
and POLD1 upon IR, DNA polymerase δ consisting of different subunits including POLD1 
(134) was identified as a putative ATR-specific phosphorylation target (155).  
 
4.6. Clinical significance of POLD1 as prognostic and predictive 
marker for personal ATR-targeted therapies 
POLD1 was previously described as a prognostic marker with conflicting data in different 
types of cancer. POLD1 overexpression is associated with a poor prognosis in hepatocellular 
carcinomas and multiple myeloma (156; 157), whereas POLD1 down-regulation is 
associated with a poor outcome in head and neck squamous cell carcinoma (158).  
Sporadic POLD1 sequence alterations have been already found in human colon cancer cell 
lines and patient tissue samples (159). A missense mutation (p.His506Arg) in the 
exonuclease domain III of DNA polymerase δ expected to cause a hypermutability 
phenotype has earlier been reported in human CRC lines (159). In addition, recently 
identified POLD1 missense mutations predispose to CRC (p.Ser478Asn, p.Pro327Arg), 
endometrial cancer (p.Ser478Asn) and likely to brain (p.Ser478Asn) and kidney tumors 
(p.Val392Met) (160; 161). Equivalent mutations of the human POLD1 p.Ser478Arg lead to an 
increased mutation rate in fission yeast and are mapped along with the human POLD1 
p.Pro327Arg mutation at the interface of the exonuclease active site predicting these 
mutations to have functional effects on DNA binding and exonuclease activity (161).  
Regarding colorectal cancer, at least 12 known CRC cell lines have been reported to harbor 
either heterozygous or homozygous mutations in POLD1 (162). As many of these mutations 
represent variants of unknown significance, future studies applying suitable syngeneic 
POLD1 model systems are urgently needed to clarify the functional significance of these 
genetic changes in CRC as well as other tumor entities. 
Thus, genetic alterations of POLD1 affecting catalytic or proofreading activity represent 
predictive markers for the therapeutic response towards ATR- and CHK1-inhibitors in the 
clinical setting. Combination treatment with radiotherapy (exemplarily shown in POLD1-
depleted DLD1 ATRs/s cells upon IR, Fig. 13) or chemotherapeutics targeting DNA directly 
(e.g. cisplatin, 5-FU) or indirectly by DNA replication or DNA repair proteins (exemplarily 
shown in POLD1-depleted DLD1 ATRs/s cells upon etoposide, Fig. 14) might increase ATR-
/CHK1-inhibitor effect in cancer cells which could improve clinical outcome.  
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5. CONCLUSION AND FURTHER PERSPECTIVE 
In conclusion, ATR-inhibition has recently been demonstrated to induce the elimination of 
CRCs (104; 106) but the underlying genetic determinants remained insufficiently defined. By 
screening of a DNA-repair gene siRNA library in a well-defined DLD1 ATR cancer cell model, 
POLD1 as one critical determinant during ATR inhibition-mediated CRC cell killing was 
identified. Synthetic lethality induced by POLD1 depletion in DLD1 ATRs/s cells was 
mechanistically described by caspase-dependent apoptosis induced by DNA damage 
accumulation. Consistent with these data, spatial co-localization of POLD1 with ATR as well 
as of POLD1 with γ-H2AX at sites of DNA damage was shown. Further, POLD1 knockdown-
induced cell killing was pharmacologically reproducible with various ATR-/CHK1-inhibitors in 
a panel of other CRC cell lines. Thus, our data might have clinical implications, as 
inactivating POLD1 mutations have recently been described in four families with multiple 
colorectal adenomas and CRC (161). In three of these POLD1 families endometrial tumors 
were diagnosed. Currently, ongoing whole-genome and whole-exome sequencing studies 
are expected to determine the POLD1 mutation rates in tumor entities other than CRC or 
endometrial cancer, which could then broaden the applicability of the identified synthetic 
lethality with ATR-inhibitors. Long-term, the development of selective POLD1- or DNA 
polymerase δ-targeted drugs should be considered to further extend the applicability of the 
proposed concept of this genotype-based anti-cancer therapy.  
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7. SUPPLEMENTARY 
7.1. List of siRNA library genes  
Table 11: siRNA library of 288 genes involved in DNA repair. 
ABCF2 DNASE2 G3BP1 MMS19 POLB RDM1 TK1 
ACLY DNMT1 HDAC1 MNAT1 POLD1 RECQL TK2 
AHCY DNMT3A HDAC2 MPG POLE RECQL4 TMEM30A 
ALKBH2 DNMT3B HDAC4 MRE11A POLG RECQL5 TOP1 
ALKBH3 DOT1L HDAC6 MRPL3 POLH REV1 TOP1MT 
APEX1 DUT HDAC10 MRPS12 POLI REV3L TOP2A 
APEX2 DVL3 HDAC11 MSH2 POLK RFC2 TOP2B 
APTX EHMT1 HELQ MSH3 POLL RFC4 TOP3A 
ATM EIF4A3 HLTF MSH4 POLM RPA1 TP53 
ATR EME1 HNRNPA2B1 MSH5 POLN RPA2 TP53BP1 
BLM ELN HSPD1 MSH6 POLQ RPA3 TPX2 
BRCA1 ENDOG HSPE1 MUS81 PPP2R5C RPA4 TRAF4 
BRCA2 ENDOV HSP90B1 MTHFD2 PRDX2 RPL13 TRDMT1 
BRIP1 ERCC1 HUS1 MUTYH PRDX4 RPL27 TREX2 
CANX ERCC2 H2AFX NBN PRIM1 RPL35 TREX1 
CARM1 ERCC3 H2AFZ NCBP2 PRKDC RRM1 TSTA3 
CBX3 ERCC4 IARS NEIL1 PRMT1 RRM2 TUBB 
CCNH ERCC5 IFNGR2 NEIL2 PSMA1 RRM2B UBE2A 
CCT4 ERCC6 ILF2 NEIL3 PSMC4 SDHC UBE2B 
CCT5 ERCC8 IL7R NHEJ1 PSME2 SEPTIN9 UBE2N 
CDK1 EXO1 INO80C NME1 PTMA SETD7 UBE2S 
CDK2 EZH2 IP6K3 NONO PTTG1 SETD8 UBE2V1 
CDK7 E2F5 KDELR2 NTHL1 RAD1 SHFM1 UBE2V2 
CDKN3 FANCA KIAA0101 NT5E RAD9A SMARCA4 UNG 
CETN2 FANCB KPNA2 NUDT1 RAD17 SMC1A WRN 
CHAF1A FANCC LDHA NUP205 RAD18 SMC3 XAB2 
CHEK1 FANCD2 LIG1 OGG1 RAD21 SMUG1 XPA 
CHEK2 FANCE LIG3 OGT RAD23A SND1 XPC 
CKS2 FANCF LIG4 ORC6 RAD23B SNRPE XRCC1 
COL1A2 FANCG MAD2L2 PAFAH1B3 RAD50 SNRPF XRCC2 
COPB2 FANCL MANF PARP1 RAD51 SOX4 XRCC3 
CRIP2 FANCM MBD1 PARP2 RAD51AP1 SPO11 XRCC4 
CRY1 FAP MBD2 PARP3 RAD51B SPRTN XRCC5 
CRY2 FBXO18 MBD3 PARP4 RAD51C SSBP1 XRCC6 
CXCL6 FEN1 MBD4 PCNA RAD51D SSR1 ZDHHC17 
C10orf2 GINS2 MCM3 PLK1 RAD52 SUV39H1 ZNF607 
DCLRE1A GMNN MECP2 PMS1 RAD54B SUV39H2 
DCLRE1B GTF2H1 MGMT PMS2 RAD54L TARS 
DCLRE1C GTF2H2 MLH1 PMS2P3 RAG1 TDG 
DDB1 GTF2H3 MLH3 PMS2P5 RAG2 TDP1 
DDB2 GTF2H4 MLL PNKP PAICS TERT 
DMC1 GTF2H5 MMP9 POLA1 RBM4 TGIF1 
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